

Supplementary Table 1 – Correct answers considered for total score calculation (according to the Brazilian Society of Immunization)

	MMR	Hepatitis A	Hepatitis B	Hepatitis A and B	Tdap or Tdap-IPV	Tetanus and diphtheria	Varicella	Influenza	Meningococcal Conjugate ACWY	Meningococcal B	Yellow Fever	PCV13	PPV23	Zoster	Dengue	Bivalent HPV	Quadrivalent HPV
All patients (regardless of age and risk group)		X ^{a)}	X ^{a)}	X ^{a)}	X ^{a)}	X ^{a)}		X ^{a)}									
Adults - 20 to 59 years old	X	X	X	X	X	X	X ^{c)}	X	X	X	X	X ^{b)}	X ^{b)}	X ^{d)}	X ^{e)}	X	X
Older adults - ≥ 60 years old	X ^{f)}	X	X	X	X	X		X	X		X	X	X	X			
Patients with chronic liver disease		X	X	X			X ^{g)}	X	X	X		X	X	X ⁱ⁾			
Patients with chronic cardiac disease and/or chronic lung disease					X		X ^{g)}	X				X	X	X ^{j)}			
Patients with neoplasms or using immunosuppressive drugs		X	X	X	X			X	X	X		X	X				
Patients with chronic kidney disease		X	X	X			X ^{g)}	X	X	X		X	X	X ^{j)}			
Patients with anatomical and functional asplenia		X	X	X			X ^{g)}	X	X	X		X	X	X			
Patients with rheumatic disease		X	X	X			X ^{g)}	X	X	X		X	X	X ^{j)}		X	X
Patients with primary immunodeficiencies		X	X	X			X ^{h)}	X	X	X		X	X	X ^{j)}		X	X
Patients with HIV/AIDS	X ⁱ⁾	X	X	X	X		X ⁱ⁾	X	X	X	X ⁱ⁾	X	X			X	X
Solid organ transplant candidates and recipients	X ^{k)}	X	X	X	X		X ^{k)}	X	X		X ^{k)}	X	X				
Patients with hematopoietic stem cell transplant	X ^{l)}	X	X	X	X		X ^{l)}	X	X		X ^{m)}	X	X				
Patients with diabetes mellitus			X				X	X				X	X				
None of the above															X		

HIV, Human Immunodeficiency Virus; AIDS, Acquired Immune Deficiency Syndrome; MMR, Measle, Mumps, and Rubella; Tdap, Tetanus, diphtheria, & acellular pertussis; IPV, Inactivated polio vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, Human papillomavirus.

a) If physician selected 'All patients (regardless of age and risk group)' the total score was 1 point (maximum score).

b) If this was the only selected item the total score was 0.

For all the cases below, although the vaccines are recommended for a given population, they are not recommended for all patients within that population. Thus, these options were considered as correct when selected by the physicians, but did not deduct points in the score if they were not selected:

c) Indicated for susceptible adults only.

d) May be recommended in patients ≥50 years, at the physician's discretion.

e) This vaccine is not always recommended for adult patients (only seropositive adults).

f) May be recommended in patients ≥60 years in certain situations (such as in cases of outbreaks), at the physician's discretion.

g) Contraindicated in patients with severe immunosuppression.

h) Contraindicated in patients with cellular or humoral immunity deficiency or with severe immunosuppression.

i) Contraindicated in patients with CD4 <200 cells/mm³ (<15%).

j) Contraindicated in immunosuppressed patients.

k) Contraindicated in the post-transplant (vaccines may be applied only when the patient is immunocompetent).

l) The use in immunocompromised patients should be evaluated by the physician.

m) The indication is dependent on epidemiological risk and the patient's immunological status.

Note: For vaccines recommended for both adult and older adult populations, but for which no special population is specified in the SBIIm immunization schedule for special populations, the option “All patients (regardless of age and risk group)” was considered as the correct one. Additionally, for those vaccines recommended for both adults and older adults, a total score of 1 point was attributed if physicians selected this option. This is because the physicians may have interpreted the “target population” solely as the age groups for which vaccines are recommended, and not the specific special populations. This may have overestimated the physicians’ knowledge regarding the vaccines’ target populations. Although the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal vaccine (PPV23) are also recommended in both adults and older adults, the recommendation in adults is valid only in the presence of certain comorbidities. As a result, the option “All patients (regardless of age and risk group)” was not considered correct for these vaccines.

Lastly, there are various instances in the SBIIm recommendations where, though a vaccine is recommended for a given special population, the recommendation does not include all patients within that population (e.g. varicella is recommended for patients with HIV/AIDS, but not in those with CD4 <200 cells/ mm³) (1). Specifying all these particularities as response options would lead to an excessively extensive survey, making it impracticable. Alternatively, the methodology described in Supplementary Table 1 footnotes was followed to avoid penalizing the physicians’ knowledge score in this question (such as physicians who did not select a special population because they were aware that the vaccine is not recommended for all patients of that population). Based on this methodology, and in these cases, the option pertaining to the special population (Supplementary Table 1) was considered as correct, but did not deduct points in the score when not selected.

Supplementary Table 2 – Correct answers for dosage schedule (according to the Brazilian Society of Immunization)

Vaccine	Dosage schedule
MMR	Two doses
Hepatitis A	Two doses
Hepatitis B	Three doses
Hepatitis A e B	Three doses
Tdap or Tdap-IPV	Booster dose every 10 years
Tetanus and diphtheria	Booster dose every 10 years
Varicella	Two doses (NA for older adults)
Influenza	Single annual dose
Meningococcal Conjugate ACWY	Single dose (the need for additional doses depends on the epidemiological situation)
Meningococcal B	Two doses (NA for older adults)
Yellow Fever	Single dose
PCV13	Sequential schedule with two vaccines (total of three doses) [NA for adults]
PPV23	Sequential schedule with two vaccines (total of three doses) [NA for adults]
Zoster	Single dose
Dengue	Three doses (NA for older adults)
Bivalent HPV	Three doses (NA for older adults)
Quadrivalent HPV	Three doses (NA for older adults)

MMR, measles, mumps, and rubella; Tdap, adult tetanus-diphtheria-acellular; IPV, Inactivated polio vaccine ; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus; NA, not applicable.

Supplementary Table 3 – Correct answers for availability in the Unified Public Health System (according to the Brazilian Society of Immunization)

Vaccine	Availability in the SUS
MMR	Yes, only in adults
Hepatitis A	Nor in adults or older adults
Hepatitis B	Yes, in adults and older adults
Hepatitis A e B	Nor in adults or older adults
Tdap or Tdap-IPV	Nor in adults or older adults
Tetanus and diphtheria	Yes, in adults and older adults
Varicella	Nor in adults or older adults
Influenza	Yes, in adults and older adults
Meningococcal Conjugate ACWY	Nor in adults or older adults
Meningococcal B	Nor in adults or older adults
Yellow Fever	Yes, in adults and older adults
PCV13	Nor in adults or older adults
PPV23*	Yes, only in older adults
Zoster	Nor in adults or older adults
Dengue	Nor in adults or older adults
Bivalent HPV	Nor in adults or older adults
Quadrivalent HPV*	Yes, only in adults

MMR, measles, mumps, and rubella; Tdap, adult tetanus-diphtheria-acellular; IPV, Inactivated polio vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus; NA, not applicable.

*Correct answers were not defined based on SBIm immunization schedules

Note: Vaccines free of charge at the Basic Health Units (BHUs) for a subset of adult and older adult patients were considered as being available in SUS for these age groups. For instance, though PPV23 is free of charge at BHUs for institutionalized older adult patients only, the option “Yes, in older adults” was considered as the correct answer. Additionally, for the Human papillomavirus (HPV) vaccine, the correct answer was not defined based on the SBIm immunization schedules. According to these schedules, no HPV vaccine is free of charge at the BHUs for the adult population. However, a document issued by the Ministry of Health (2) states that the quadrivalent HPV is in fact available at the BHUs for men and women up to 26 years old with HIV/AIDS or immunosuppressed (oncology patients and those submitted to a solid organ or bone marrow transplantation). Thus, the correct answer was considered as “Yes, in adults”. For PCV13, the correct answer considered was “Nor in adult or older adults”, according to the National Vaccination Calendar at the time of this survey (3).

Supplementary Table 4 – Number of required completed surveys per medical specialty and Brazilian region

Specialty \ Region	Region					
	North	Northeast	Midwest	Southeast	South	Total
Cardiology	11	44	20	133	36	244
GP/FM	4	15	7	46	13	85
Endocrinology	4	14	7	43	12	80
Geriatrics	1	5	2	14	4	26
Gynecology	23	92	42	280	78	515
Infectious disease	3	10	5	32	9	59
Pulmonology	2	11	5	32	9	59
Total	48	191	88	580	161	1068

GP/FP, general practitioners/family medicine

Supplementary Table 5 – Proportions of physicians not prescribing the vaccines recommended by the Brazilian Society of Immunization to all adult and older adult patients with an indication

Vaccine	Adults	Older adults
MMR	18.2% (100 out of 550)	12.4% (31 out of 249)
Hepatitis A	22.0% (82 out of 373)	14.4% (37 out of 257)
Hepatitis B	10.9% (101 out of 925)	12.2% (77 out of 630)
Hepatitis A and B	19.8% (99 out of 499)	11.8% (33 out of 279)
Tdap or Tdap-IPV	12.0% (86 out of 719)	18.3% (69 out of 378)
Tetanus and diphtheria	14.5% (112 out of 774)	15.5% (86 out of 556)
Varicella	18.6% (52 out of 279)	NA
Influenza	6.7% (68 out of 1013)	8.4% (83 out of 991)
Meningococcal Conjugate ACWY	22.7% (49 out of 216)	14.4% (23 out of 160)
Meningococcal B	18.9% (38 out of 201)	NA
Yellow Fever	12.5% (104 out of 830)	17.0% (106 out of 625)
PCV13	16.9% (89 out of 528)	16.8% (90 out of 536)
PPV23	12.6% (62 out of 494)	13.8% (75 out of 544)
Zoster	24.0% (119 out of 496)	23.1% (120 out of 520)
Dengue	16.4% (35 out of 213)	NA
Bivalent HPV	12.8% (64 out of 499)	NA
Quadrivalent HPV	9.1% (58 out of 638)	NA

MMR, measles, mumps, and rubella; Tdap, adult tetanus-diphtheria-acellular; IPV, Inactivated polio vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus; NA, not applicable.

Note: Proportions were determined based on the number of physicians who indicated to prescribe each vaccine to adults and older adults.

Supplementary Table 6 – Reasons for non-prescription of adult recommended vaccines

Vaccine, n (%)	Vaccine does not belong to the scope of the physicians' specialty	Physician does not provide care for patients in this age group	Vaccine is not available through SUS	High vaccine cost	Fear of side effects	Doubts regarding the vaccine's indication
MMR	337 (65.1%)	51 (9.8%)	12 (2.3%)	8 (1.5%)	12 (2.3%)	84 (16.2%)
Hepatitis A	432 (62.2%)	38 (5.5%)	100 (14.4%)	41 (5.9%)	18 (2.6%)	136 (19.6%)
Hepatitis B	112 (78.3%)	6 (4.2%)	3 (2.1%)	2 (1.4%)	2 (1.4%)	16 (11.2%)
Hepatitis A and B	297 (52.2%)	25 (4.4%)	105 (18.5%)	46 (8.1%)	16 (2.8%)	96 (16.9%)
Tdap or Tdap-IPV	247 (70.8%)	23 (6.6%)	19 (5.4%)	10 (2.9%)	12 (3.4%)	57 (16.3%)
Tetanus and diphtheria	206 (70.1%)	14 (4.8%)	6 (2.0%)	5 (1.7%)	7 (2.4%)	30 (10.2%)
Varicella	512 (64.9%)	62 (7.9%)	69 (8.7%)	42 (5.3%)	29 (3.7%)	121 (15.3%)
Influenza	33 (60.0%)	3 (5.5%)	3 (5.5%)	3 (5.5%)	2 (3.6%)	4 (7.3%)
Meningococcal Conjugate ACWY	611 (71.7%)	60 (7.0%)	96 (11.3%)	91 (10.7%)	34 (4.0%)	148 (17.4%)
Meningococcal B	622 (71.7%)	58 (6.7%)	74 (8.5%)	84 (9.7%)	32 (3.7%)	146 (16.8%)
Yellow Fever	184 (77.3%)	7 (2.9%)	5 (2.1%)	4 (1.7%)	10 (4.2%)	17 (7.1%)
PCV13	383 (70.9%)	24 (4.4%)	44 (8.1%)	36 (6.7%)	15 (2.8%)	82 (15.2%)
PPV23	398 (69.3%)	20 (3.5%)	47 (8.2%)	42 (7.3%)	12 (2.1%)	103 (17.9%)
Zoster	309 (54.0%)	15 (2.6%)	80 (14.0%)	67 (11.7%)	36 (6.3%)	145 (25.3%)
Dengue	392 (45.8%)	14 (1.6%)	126 (14.7%)	71 (8.3%)	114 (13.3%)	205 (24.0%)
Bivalent HPV	302 (53.1%)	51 (9.0%)	36 (6.3%)	25 (4.4%)	20 (3.5%)	67 (11.8%)
Quadrivalent HPV	296 (68.8%)	47 (10.9%)	41 (9.5%)	38 (8.8%)	19 (4.4%)	73 (17.0%)

MMR, measles, mumps, and rubella; Tdap, adult tetanus-diphtheria-acellular; IPV, Inactivated polio vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus.

Note: For each reason, the proportion was determined based on the physicians who stated not to prescribe each vaccine to adult patients.

Supplementary Table 6 – Reasons for non-prescription of adult recommended vaccines (continuation)

Vaccine, n (%)	Doubts regarding the vaccine's efficacy	Lack of time during the appointment	Lack of patient interest	Vaccine is not refundable under the list of the National Supplementary Health Agency	Other reason
MMR	9 (1.7%)	46 (8.9%)	57 (11.0%)	11 (2.1%)	101 (19.5%)
Hepatitis A	33 (4.7%)	68 (9.8%)	105 (15.1%)	27 (3.9%)	117 (16.8%)
Hepatitis B	2 (1.4%)	14 (9.8%)	13 (9.1%)	2 (1.4%)	20 (14.0%)
Hepatitis A and B	19 (3.3%)	45 (7.9%)	58 (10.2%)	17 (3.0%)	124 (21.8%)
Tdap or Tdap-IPV	8 (2.3%)	34 (9.7%)	37 (10.6%)	7 (2.0%)	52 (14.9%)
Tetanus and diphtheria	7 (2.4%)	32 (10.9%)	31 (10.5%)	6 (2.0%)	56 (19.0%)
Varicella	20 (2.5%)	56 (7.1%)	90 (11.4%)	19 (2.4%)	123 (15.6%)
Influenza	4 (7.3%)	4 (7.3%)	2 (3.6%)	1 (1.8%)	13 (23.6%)
Meningococcal Conjugate ACWY	25 (2.9%)	49 (5.8%)	74 (8.7%)	30 (3.5%)	90 (10.6%)
Meningococcal B	23 (2.7%)	56 (6.5%)	83 (9.6%)	28 (3.2%)	114 (13.1%)
Yellow Fever	5 (2.1%)	16 (6.7%)	18 (7.6%)	5 (2.1%)	38 (16.0%)
PCV13	12 (2.2%)	35 (6.5%)	45 (8.3%)	13 (2.4%)	71 (13.1%)
PPV23	19 (3.3%)	38 (6.6%)	45 (7.8%)	13 (2.3%)	81 (14.1%)
Zoster	46 (8.0%)	32 (5.6%)	50 (8.7%)	15 (2.6%)	76 (13.3%)
Dengue	200 (23.4%)	44 (5.1%)	59 (6.9%)	27 (3.2%)	157 (18.4%)
Bivalent HPV	47 (8.3%)	24 (4.2%)	32 (5.6%)	14 (2.5%)	159 (27.9%)
Quadrivalent HPV	25 (5.8%)	24 (5.6%)	28 (6.5%)	13 (3.0%)	50 (11.6%)

MMR, measles, mumps, and rubella; Tdap, adult tetanus-diphtheria-acellular; IPV, Inactivated polio vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus.

Note: For each reason, the proportion was determined based on the physicians who stated not to prescribe each vaccine to adult patients.

Supplementary Table 7 – Reasons for non-prescription of older adult recommended vaccines

Vaccine, n (%)	Vaccine does not belong to the scope of the physicians' specialty	Physician does not provide care for patients in this age group	Vaccine is not available through SUS	High vaccine cost	Fear of side effects	Doubts regarding the vaccine's indication
MMR	484 (59.1%)	40 (4.9%)	16 (2.0%)	10 (1.2%)	53 (6.5%)	156 (19.0%)
Hepatitis A	486 (59.9%)	32 (3.9%)	60 (7.4%)	25 (3.1%)	27 (3.3%)	131 (16.2%)
Hepatitis B	263 (60.0%)	22 (5.0%)	8 (1.8%)	5 (1.1%)	21 (4.8%)	59 (13.5%)
Hepatitis A and B	418 (53.0%)	27 (3.4%)	90 (11.4%)	59 (7.5%)	24 (3.0%)	135 (17.1%)
Tdap or Tdap-IPV	421 (61.0%)	30 (4.3%)	38 (5.5%)	21 (3.0%)	38 (5.5%)	119 (17.2%)
Tetanus and diphtheria	329 (64.3%)	25 (4.9%)	5 (1.0%)	5 (1.0%)	24 (4.7%)	61 (11.9%)
Influenza	47 (61.0%)	13 (16.9%)	2 (2.6%)	2 (2.6%)	7 (9.1%)	2 (2.6%)
Meningococcal Conjugate ACWY	587 (64.6%)	39 (4.3%)	78 (8.6%)	76 (8.4%)	45 (5.0%)	164 (18.1%)
Yellow Fever	232 (52.4%)	21 (4.7%)	4 (0.9%)	5 (1.1%)	121 (27.3%)	45 (10.2%)
PCV13	351 (66.0%)	24 (4.5%)	42 (7.9%)	31 (5.8%)	20 (3.8%)	68 (12.8%)
PPV23	352 (67.2%)	21 (4.0%)	38 (7.3%)	33 (6.3%)	20 (3.8%)	86 (16.4%)
Zoster	315 (57.5%)	24 (4.4%)	61 (11.1%)	58 (10.6%)	30 (5.5%)	126 (23.0%)

MMR, measles, mumps, and rubella; Tdap, adult tetanus-diphtheria-acellular; IPV, Inactivated polio vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus.

Note: For each reason, the proportion was determined based on the physicians who stated not to prescribe each vaccine to older adult patients.

Supplementary Table 7 – Reasons for non-prescription of older adult recommended vaccines (continuation)

Vaccine	Doubts regarding the vaccine's efficacy	Lack of time during the appointment	Lack of patient interest	Vaccine is not refundable under the list of the National Supplementary Health Agency	Other reason
MMR	23 (2.8%)	42 (5.1%)	59 (7.2%)	12 (1.5%)	167 (20.4%)
Hepatitis A	32 (3.9%)	47 (5.8%)	76 (9.4%)	14 (1.7%)	169 (20.8%)
Hepatitis B	11 (2.5%)	29 (6.6%)	40 (9.1%)	4 (0.9%)	91 (20.8%)
Hepatitis A and B	32 (4.1%)	51 (6.5%)	68 (8.6%)	18 (2.3%)	176 (22.3%)
Tdap or Tdap-IPV	14 (2.0%)	42 (6.1%)	51 (7.4%)	15 (2.2%)	127 (18.4%)
Tetanus and diphtheria	11 (2.1%)	43 (8.4%)	42 (8.2%)	4 (0.8%)	104 (20.3%)
Influenza	2 (2.6%)	4 (5.2%)	2 (2.6%)	1 (1.3%)	15 (19.5%)
Meningococcal Conjugate ACWY	30 (3.3%)	46 (5.1%)	61 (6.7%)	22 (2.4%)	136 (15.0%)
Yellow Fever	14 (3.2%)	20 (4.5%)	24 (5.4%)	5 (1.1%)	76 (17.2%)
PCV13	18 (3.4%)	34 (6.4%)	26 (4.9%)	12 (2.3%)	96 (18.0%)
PPV23	16 (3.1%)	37 (7.1%)	27 (5.2%)	9 (1.7%)	74 (14.1%)
Zoster	48 (8.8%)	38 (6.9%)	34 (6.2%)	10 (1.8%)	65 (11.9%)

MMR, measles, mumps, and rubella; Tdap, adult tetanus-diphtheria-acellular; IPV, Inactivated polio vaccine ; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus.

Note: For each reason, the proportion was determined based on the physicians who stated not to prescribe each vaccine to older adult patients.

Supplementary Table 8 – Reasons for underprescription of adult recommended vaccines

Vaccine, n (%)	Vaccine is not available through SUS	High vaccine cost	Fear of side effects	Doubts regarding the vaccine's indication	Doubts regarding the vaccine's efficacy
MMR	18 (22.2%)	14 (17.3%)	10 (12.3%)	18 (22.2%)	3 (3.7%)
Hepatitis A	38 (56.7%)	20 (29.9%)	1 (1.5%)	3 (4.5%)	2 (3.0%)
Hepatitis B	9 (10.5%)	12 (14.0%)	6 (7.0%)	18 (20.9%)	5 (5.8%)
Hepatitis A and B	33 (37.9%)	25 (28.7%)	4 (4.6%)	8 (9.2%)	3 (3.4%)
Tdap or Tdap-IPV	16 (22.5%)	10 (14.1%)	7 (9.9%)	13 (18.3%)	5 (7.0%)
Tetanus and diphtheria	3 (3.4%)	3 (3.4%)	8 (9.0%)	11 (12.4%)	5 (5.6%)
Varicella	16 (45.7%)	13 (37.1%)	7 (20.0%)	3 (8.6%)	1 (2.9%)
Influenza	4 (7.4%)	4 (7.4%)	10 (18.5%)	11 (20.4%)	8 (14.8%)
Meningococcal Conjugate ACWY	25 (64.1%)	24 (61.5%)	3 (7.7%)	7 (17.9%)	1 (2.6%)
Meningococcal B	14 (48.3%)	17 (58.6%)	5 (17.2%)	5 (17.2%)	1 (3.4%)
Yellow Fever	0 (0.0%)	0 (0.0%)	34 (40.0%)	19 (22.4%)	3 (3.5%)
PCV13	29 (37.7%)	36 (46.8%)	6 (7.8%)	18 (23.4%)	8 (10.4%)
PPV23	11 (20.8%)	20 (37.7%)	9 (17.0%)	13 (24.5%)	6 (11.3%)
Zoster	52 (53.6%)	67 (69.1%)	9 (9.3%)	17 (17.5%)	9 (9.3%)
Dengue	10 (34.5%)	14 (48.3%)	9 (31.0%)	11 (37.9%)	10 (34.5%)
Bivalent HPV	16 (30.2%)	31 (58.5%)	4 (7.5%)	9 (17.0%)	3 (5.7%)
Quadrivalent HPV	22 (47.8%)	34 (73.9%)	3 (6.5%)	6 (13.0%)	1 (2.2%)

MMR, measles, mumps, and rubella; Tdap, adult tetanus-diphtheria-acellular; IPV, Inactivated polio vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus.

Note: For each reason, the proportion was determined based on the physicians who stated to underprescribe each vaccine to adult patients.

Supplementary Table 8 – Reasons for underprescription of adult recommended vaccines (continuation)

Vaccine, n (%)	Lack of time during the appointment	Lack of patient interest	Vaccine is not refundable under the list of the National Supplementary Health Agency	Other reason
MMR	44 (54.3%)	49 (60.5%)	12 (14.8%)	14 (17.3%)
Hepatitis A	18 (26.9%)	29 (43.3%)	9 (13.4%)	9 (13.4%)
Hepatitis B	44 (51.2%)	30 (34.9%)	3 (3.5%)	16 (18.6%)
Hepatitis A and B	30 (34.5%)	34 (39.1%)	11 (12.6%)	17 (19.5%)
Tdap or Tdap-IPV	34 (47.9%)	28 (39.4%)	5 (7.0%)	16 (22.5%)
Tetanus and diphtheria	54 (60.7%)	34 (38.2%)	2 (2.2%)	16 (18.0%)
Varicella	9 (25.7%)	11 (31.4%)	3 (8.6%)	7 (20.0%)
Influenza	26 (48.1%)	20 (37.0%)	3 (5.6%)	12 (22.2%)
Meningococcal Conjugate ACWY	6 (15.4%)	9 (23.1%)	9 (23.1%)	8 (20.5%)
Meningococcal B	3 (10.3%)	7 (24.1%)	6 (20.7%)	3 (10.3%)
Yellow Fever	33 (38.8%)	24 (28.2%)	0 (0.0%)	16 (18.8%)
PCV13	17 (22.1%)	21 (27.3%)	12 (15.6%)	12 (15.6%)
PPV23	21 (39.6%)	14 (26.4%)	8 (15.1%)	9 (17.0%)
Zoster	21 (21.6%)	22 (22.7%)	23 (23.7%)	7 (7.2%)
Dengue	8 (27.6%)	11 (37.9%)	6 (20.7%)	2 (6.9%)
Bivalent HPV	9 (17.0%)	16 (30.2%)	6 (11.3%)	11 (20.8%)
Quadrivalent HPV	8 (17.4%)	11 (23.9%)	7 (15.2%)	4 (8.7%)

MMR, measles, mumps, and rubella; Tdap, adult tetanus-diphtheria-acellular; IPV, Inactivated polio vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus.

Note: For each reason, the proportion was determined based on the physicians who stated to underprescribe each vaccine to adult patients.

Supplementary Table 9 – Reasons for underprescription of older adult recommended vaccines

Vaccine, n (%)	Vaccine is not available through SUS	High vaccine cost	Fear of side effects	Doubts regarding the vaccine's indication	Doubts regarding the vaccine's efficacy
MMR	1 (4.5%)	1 (4.5%)	4 (18.2%)	3 (13.6%)	0
Hepatitis A	12 (37.5%)	9 (28.1%)	3 (9.4%)	4 (12.5%)	0
Hepatitis B	0	3 (4.5%)	5 (7.5%)	12 (17.9%)	3 (4.5%)
Hepatitis A and B	9 (36.0%)	7 (28.0%)	1 (4.0%)	3 (12.0%)	1 (4.0%)
Tdap or Tdap-IPV	9 (16.1%)	6 (10.7%)	6 (10.7%)	5 (8.9%)	2 (3.6%)
Tetanus and diphtheria	3 (4.2%)	3 (4.2%)	4 (5.6%)	11 (15.3%)	2 (2.8%)
Influenza	2 (2.7%)	5 (6.8%)	9 (12.2%)	7 (9.5%)	8 (10.8%)
Meningococcal Conjugate ACWY	9 (52.9%)	11 (64.7%)	2 (11.8%)	1 (5.9%)	0
Yellow Fever	0	0	34 (47.2%)	11 (15.3%)	1 (1.4%)
PCV13	28 (35.4%)	38 (48.1%)	8 (10.1%)	13 (16.5%)	6 (7.6%)
PPV23	16 (22.9%)	29 (41.4%)	10 (14.3%)	11 (15.7%)	8 (11.4%)
Zoster	59 (57.8%)	72 (70.6%)	11 (10.8%)	14 (13.7%)	9 (8.8%)

MMR, measles, mumps, and rubella; Tdap, adult tetanus-diphtheria-acellular; IPV, Inactivated polio vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus.

Note: For each reason, the proportion was determined based on the physicians who stated to underprescribe each vaccine to older adult patients.

Supplementary Table 9 – Reasons for underprescription of older adult recommended vaccines (continuation)

Vaccine, n (%)	Lack of time during the appointment	Lack of patient interest	Vaccine is not refundable under the list of the National Supplementary Health Agency	Other reason
MMR	6 (27.3%)	14 (63.6%)	1 (4.5%)	8 (36.4%)
Hepatitis A	8 (25.0%)	12 (37.5%)	5 (15.6%)	7 (21.9%)
Hepatitis B	29 (43.3%)	30 (44.8%)	0	20 (29.9%)
Hepatitis A and B	8 (32.0%)	7 (28.0%)	3 (12.0%)	6 (24.0%)
Tdap or Tdap-IPV	20 (35.7%)	24 (42.9%)	2 (3.6%)	14 (25.0%)
Tetanus and diphtheria	36 (50.0%)	24 (33.3%)	2 (2.8%)	23 (31.9%)
Influenza	37 (50.0%)	26 (35.1%)	2 (2.7%)	17 (23.0%)
Meningococcal Conjugate ACWY	3 (17.6%)	8 (47.1%)	3 (17.6%)	1 (5.9%)
Yellow Fever	19 (26.4%)	12 (16.7%)	0	18 (25.0%)
PCV13	25 (31.6%)	19 (24.1%)	11 (13.9%)	15 (19.0%)
PPV23	21 (30.0%)	16 (22.9%)	11 (15.7%)	17 (24.3%)
Zoster	27 (26.5%)	24 (23.5%)	21 (20.6%)	10 (9.8%)

MMR, measles, mumps, and rubella; Tdap, adult tetanus-diphtheria-acellular; IPV, Inactivated polio vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus.

Note: For each reason, the proportion was determined based on the physicians who stated to underprescribe each vaccine to older adult patients.

Supplementary Table 10 – Knowledge of vaccines – Target populations in accordance with the recommendations of the Brazilian Society of Immunization by medical specialties

	Cardiology (n=244)	General Practice/Family Practice (n=85)	Endocrinology (n=80)	Geriatrics (n=26)	Gynecology (n=515)	Infectious Diseases (n=59)	Pulmonology (n=59)
MMR (measles, mumps and rubella), n (%)							
All patients (regardless of age and risk group)	30 (33.7%)	18 (30.5%)	5 (16.7%)	3 (37.5%)	93 (29.9%)	10 (18.2%)	11 (40.7%)
Adults - 20 to 59 years old	40 (44.9%)	34 (57.6%)	17 (56.7%)	4 (50.0%)	180 (57.9%)	43 (78.2%)	15 (55.6%)
Older adults - ≥ 60 years old	12 (13.5%)	9 (15.3%)	5 (16.7%)	1 (12.5%)	23 (7.4%)	9 (16.4%)	3 (11.1%)
Patients with chronic liver disease	6 (6.7%)	4 (6.8%)	3 (10.0%)	1 (12.5%)	5 (1.6%)	9 (16.4%)	0
Patients with chronic cardiac disease and/or chronic lung disease	10 (11.2%)	6 (10.2%)	7 (23.3%)	2 (25.0%)	13 (4.2%)	6 (10.9%)	4 (14.8%)
Patients with neoplasms or using immunosuppressive drugs	4 (4.5%)	5 (8.5%)	3 (10.0%)	0	9 (2.9%)	2 (3.6%)	1 (3.7%)
Patients with chronic kidney disease	6 (6.7%)	5 (8.5%)	3 (10.0%)	1 (12.5%)	11 (3.5%)	3 (5.5%)	0
Patients with anatomical and functional asplenia	4 (4.5%)	2 (3.4%)	6 (20.0%)	0	8 (2.6%)	4 (7.3%)	0
Patients with rheumatic disease	6 (6.7%)	4 (6.8%)	4 (13.3%)	1 (12.5%)	8 (2.6%)	4 (7.3%)	1 (3.7%)
Patients with primary immunodeficiencies	5 (5.6%)	6 (10.2%)	2 (6.7%)	1 (12.5%)	10 (3.2%)	0	1 (3.7%)
Patients with HIV/AIDS	6 (6.7%)	7 (11.9%)	5 (16.7%)	1 (12.5%)	11 (3.5%)	11 (20.0%)	0
Solid organ transplant candidates and recipients	9 (10.1%)	4 (6.8%)	4 (13.3%)	0	11 (3.5%)	3 (5.5%)	1 (3.7%)
Patients with hematopoietic stem cell transplant	4 (4.5%)	2 (3.4%)	3 (10.0%)	0	5 (1.6%)	1 (1.8%)	0
Patients with diabetes mellitus	10 (11.2%)	5 (8.5%)	5 (16.7%)	0	9 (2.9%)	7 (12.7%)	1 (3.7%)
None of the above	9 (10.1%)	3 (5.1%)	2 (6.7%)	1 (12.5%)	35 (11.3%)	0	0
Total score							
N	89	59	30	8	311	55	27
Mean	0.37	0.47	0.45	0.25	0.53	0.65	0.44
Standard deviation	0.47	0.48	0.50	0.46	0.49	0.45	0.49
Median	0.00	0.33	0.00	0.00	1.00	1.00	0.00
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Hepatitis A, n (%)							
All patients (regardless of age and risk group)	48 (57.8%)	20 (42.6%)	16 (51.6%)	4 (36.4%)	73 (48.3%)	23 (41.8%)	12 (66.7%)
Adults - 20 to 59 years old	17 (20.5%)	18 (38.3%)	6 (19.4%)	1 (9.1%)	44 (29.1%)	14 (25.5%)	6 (33.3%)
Older adults - ≥ 60 years old	6 (7.2%)	6 (12.8%)	1 (3.2%)	0	11 (7.3%)	6 (10.9%)	0
Patients with chronic liver disease	11 (13.3%)	9 (19.1%)	8 (25.8%)	0	12 (7.9%)	25 (45.5%)	2 (11.1%)
Patients with chronic cardiac disease and/or chronic lung disease	4 (4.8%)	3 (6.4%)	4 (12.9%)	0	10 (6.6%)	3 (5.5%)	2 (11.1%)
Patients with neoplasms or using immunosuppressive drugs	4 (4.8%)	1 (2.1%)	2 (6.5%)	0	10 (6.6%)	5 (9.1%)	1 (5.6%)
Patients with chronic kidney disease	4 (4.8%)	4 (8.5%)	3 (9.7%)	0	8 (5.3%)	4 (7.3%)	1 (5.6%)

Patients with anatomical and functional asplenia	3 (3.6%)	0	3 (9.7%)	0	7 (4.6%)	5 (9.1%)	0
Patients with rheumatic disease	3 (3.6%)	3 (6.4%)	3 (9.7%)	0	7 (4.6%)	4 (7.3%)	0
Patients with primary immunodeficiencies	9 (10.8%)	1 (2.1%)	4 (12.9%)	1 (9.1%)	11 (7.3%)	9 (16.4%)	1 (5.6%)
Patients with HIV/AIDS	11 (13.3%)	5 (10.6%)	3 (9.7%)	1 (9.1%)	18 (11.9%)	25 (45.5%)	0
Solid organ transplant candidates and recipients	6 (7.2%)	2 (4.3%)	4 (12.9%)	0	10 (6.6%)	12 (21.8%)	0
Patients with hematopoietic stem cell transplant	5 (6.0%)	2 (4.3%)	2 (6.5%)	0	6 (4.0%)	6 (10.9%)	0
Patients with diabetes mellitus	8 (9.6%)	5 (10.6%)	4 (12.9%)	0	9 (6.0%)	6 (10.9%)	0
None of the above	8 (9.6%)	4 (8.5%)	2 (6.5%)	5 (45.5%)	20 (13.2%)	0	0

Total score

N	83	47	31	11	151	55	18
Mean	0.65	0.51	0.61	0.39	0.56	0.59	0.71
Standard deviation	0.43	0.44	0.43	0.49	0.45	0.38	0.42
Median	1.00	0.36	1.00	0.09	0.64	0.55	1.00
Minimum	0.00	0.00	0.00	0.00	0.00	0.09	0.09
Maximum	1.00	1.00	1.00	1.00	1.00	1.00	1.00

Hepatitis B, n (%)

All patients (regardless of age and risk group)	105 (56.1%)	41 (54.7%)	39 (60.0%)	11 (47.8%)	280 (57.3%)	42 (71.2%)	23 (62.2%)
Adults - 20 to 59 years old	51 (27.3%)	30 (40.0%)	14 (21.5%)	6 (26.1%)	163 (33.3%)	15 (25.4%)	12 (32.4%)
Older adults - ≥ 60 years old	26 (13.9%)	17 (22.7%)	7 (10.8%)	6 (26.1%)	47 (9.6%)	6 (10.2%)	3 (8.1%)
Patients with chronic liver disease	22 (11.8%)	9 (12.0%)	11 (16.9%)	5 (21.7%)	29 (5.9%)	8 (13.6%)	9 (24.3%)
Patients with chronic cardiac disease and/or chronic lung disease	19 (10.2%)	4 (5.3%)	7 (10.8%)	5 (21.7%)	16 (3.3%)	6 (10.2%)	6 (16.2%)
Patients with neoplasms or using immunosuppressive drugs	16 (8.6%)	4 (5.3%)	5 (7.7%)	2 (8.7%)	16 (3.3%)	3 (5.1%)	1 (2.7%)
Patients with chronic kidney disease	19 (10.2%)	6 (8.0%)	6 (9.2%)	4 (17.4%)	19 (3.9%)	8 (13.6%)	2 (5.4%)
Patients with anatomical and functional asplenia	12 (6.4%)	3 (4.0%)	5 (7.7%)	3 (13.0%)	16 (3.3%)	3 (5.1%)	4 (10.8%)
Patients with rheumatic disease	7 (3.7%)	3 (4.0%)	5 (7.7%)	2 (8.7%)	11 (2.2%)	4 (6.8%)	0
Patients with primary immunodeficiencies	19 (10.2%)	3 (4.0%)	6 (9.2%)	1 (4.3%)	23 (4.7%)	3 (5.1%)	3 (8.1%)
Patients with HIV/AIDS	27 (14.4%)	6 (8.0%)	9 (13.8%)	1 (4.3%)	37 (7.6%)	7 (11.9%)	2 (5.4%)
Solid organ transplant candidates and recipients	22 (11.8%)	4 (5.3%)	6 (9.2%)	2 (8.7%)	28 (5.7%)	6 (10.2%)	5 (13.5%)
Patients with hematopoietic stem cell transplant	18 (9.6%)	3 (4.0%)	5 (7.7%)	1 (4.3%)	14 (2.9%)	7 (11.9%)	3 (8.1%)
Patients with diabetes mellitus	16 (8.6%)	6 (8.0%)	7 (10.8%)	3 (13.0%)	16 (3.3%)	4 (6.8%)	2 (5.4%)
None of the above	5 (2.7%)	0	4 (6.2%)	2 (8.7%)	31 (6.3%)	1 (1.7%)	0

Total score

N	187	75	65	23	489	59	37
Mean	0.67	0.65	0.70	0.59	0.64	0.81	0.71
Standard deviation	0.40	0.40	0.41	0.43	0.43	0.33	0.39
Median	1.00	1.00	1.00	0.83	1.00	1.00	1.00
Minimum	0.00	0.08	0.00	0.00	0.00	0.00	0.08
Maximum	1.00	1.00	1.00	1.00	1.00	1.00	1.00

Hepatitis A and B, n (%)

All patients (regardless of age and risk group)	52 (51.0%)	18 (33.3%)	15 (36.6%)	5 (41.7%)	111 (45.5%)	22 (53.7%)	13 (59.1%)
Adults - 20 to 59 years old	22 (21.6%)	20 (37.0%)	14 (34.1%)	3 (25.0%)	81 (33.2%)	13 (31.7%)	5 (22.7%)
Older adults - ≥ 60 years old	16 (15.7%)	15 (27.8%)	2 (4.9%)	1 (8.3%)	24 (9.8%)	3 (7.3%)	0
Patients with chronic liver disease	15 (14.7%)	9 (16.7%)	14 (34.1%)	3 (25.0%)	20 (8.2%)	15 (36.6%)	3 (13.6%)
Patients with chronic cardiac disease and/or chronic lung disease	12 (11.8%)	5 (9.3%)	7 (17.1%)	2 (16.7%)	13 (5.3%)	3 (7.3%)	4 (18.2%)
Patients with neoplasms or using immunosuppressive drugs	10 (9.8%)	4 (7.4%)	7 (17.1%)	0	14 (5.7%)	5 (12.2%)	2 (9.1%)
Patients with chronic kidney disease	10 (9.8%)	5 (9.3%)	8 (19.5%)	2 (16.7%)	13 (5.3%)	6 (14.6%)	1 (4.5%)
Patients with anatomical and functional asplenia	7 (6.9%)	3 (5.6%)	8 (19.5%)	1 (8.3%)	13 (5.3%)	3 (7.3%)	3 (13.6%)
Patients with rheumatic disease	5 (4.9%)	5 (9.3%)	7 (17.1%)	1 (8.3%)	13 (5.3%)	4 (9.8%)	1 (4.5%)
Patients with primary immunodeficiencies	13 (12.7%)	4 (7.4%)	6 (14.6%)	0	16 (6.6%)	6 (14.6%)	2 (9.1%)
Patients with HIV/AIDS	16 (15.7%)	4 (7.4%)	7 (17.1%)	0	21 (8.6%)	13 (31.7%)	1 (4.5%)
Solid organ transplant candidates and recipients	12 (11.8%)	4 (7.4%)	6 (14.6%)	0	18 (7.4%)	8 (19.5%)	1 (4.5%)
Patients with hematopoietic stem cell transplant	7 (6.9%)	3 (5.6%)	6 (14.6%)	0	10 (4.1%)	7 (17.1%)	1 (4.5%)
Patients with diabetes mellitus	10 (9.8%)	6 (11.1%)	5 (12.2%)	1 (8.3%)	6 (2.5%)	3 (7.3%)	0
None of the above	14 (13.7%)	10 (18.5%)	4 (9.8%)	2 (16.7%)	35 (14.3%)	0	2 (9.1%)
Total score							
N	102	54	41	12	244	41	22
Mean	0.61	0.44	0.53	0.48	0.54	0.71	0.66
Standard deviation	0.43	0.43	0.42	0.47	0.45	0.36	0.45
Median	1.00	0.18	0.64	0.23	0.59	1.00	1.00
Minimum	0.00	0.00	0.00	0.00	0.00	0.09	0.00
Maximum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Tdap or Tdap-IPV, n (%)							
All patients (regardless of age and risk group)	49 (45.8%)	25 (40.3%)	18 (42.9%)	7 (35.0%)	185 (42.0%)	26 (44.8%)	15 (46.9%)
Adults - 20 to 59 years old	28 (26.2%)	18 (29.0%)	7 (16.7%)	6 (30.0%)	147 (33.4%)	15 (25.9%)	13 (40.6%)
Older adults - ≥ 60 years old	13 (12.1%)	13 (21.0%)	6 (14.3%)	3 (15.0%)	40 (9.1%)	7 (12.1%)	9 (28.1%)
Patients with chronic liver disease	9 (8.4%)	3 (4.8%)	3 (7.1%)	1 (5.0%)	16 (3.6%)	3 (5.2%)	3 (9.4%)
Patients with chronic cardiac disease and/or chronic lung disease	13 (12.1%)	2 (3.2%)	4 (9.5%)	1 (5.0%)	24 (5.5%)	5 (8.6%)	9 (28.1%)
Patients with neoplasms or using immunosuppressive drugs	4 (3.7%)	3 (4.8%)	6 (14.3%)	1 (5.0%)	21 (4.8%)	7 (12.1%)	2 (6.3%)
Patients with chronic kidney disease	9 (8.4%)	5 (8.1%)	4 (9.5%)	1 (5.0%)	17 (3.9%)	4 (6.9%)	2 (6.3%)
Patients with anatomical and functional asplenia	5 (4.7%)	4 (6.5%)	6 (14.3%)	1 (5.0%)	18 (4.1%)	7 (12.1%)	2 (6.3%)
Patients with rheumatic disease	8 (7.5%)	3 (4.8%)	2 (4.8%)	3 (15.0%)	14 (3.2%)	6 (10.3%)	2 (6.3%)
Patients with primary immunodeficiencies	6 (5.6%)	7 (11.3%)	5 (11.9%)	0	28 (6.4%)	8 (13.8%)	2 (6.3%)
Patients with HIV/AIDS	8 (7.5%)	6 (9.7%)	5 (11.9%)	2 (10.0%)	37 (8.4%)	7 (12.1%)	2 (6.3%)
Solid organ transplant candidates and recipients	8 (7.5%)	4 (6.5%)	6 (14.3%)	1 (5.0%)	25 (5.7%)	9 (15.5%)	1 (3.1%)
Patients with hematopoietic stem cell transplant	6 (5.6%)	3 (4.8%)	5 (11.9%)	0	22 (5.0%)	9 (15.5%)	1 (3.1%)
Patients with diabetes mellitus	9 (8.4%)	5 (8.1%)	4 (9.5%)	1 (5.0%)	16 (3.6%)	3 (5.2%)	3 (9.4%)
None of the above	16 (15.0%)	10 (16.1%)	7 (16.7%)	5 (25.0%)	85 (19.3%)	6 (10.3%)	1 (3.1%)

Total score							
N	107	62	42	20	440	58	32
Mean	0.52	0.48	0.50	0.41	0.49	0.53	0.59
Standard deviation	0.45	0.44	0.46	0.45	0.44	0.44	0.41
Median	0.29	0.29	0.29	0.14	0.29	0.36	0.57
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Tetanus and diphtheria, n (%)							
All patients (regardless of age and risk group)	80 (56.3%)	34 (47.9%)	33 (63.5%)	13 (61.9%)	234 (54.4%)	43 (75.4%)	20 (60.6%)
Adults - 20 to 59 years old	36 (25.4%)	29 (40.8%)	13 (25.0%)	6 (28.6%)	151 (35.1%)	13 (22.8%)	11 (33.3%)
Older adults - ≥ 60 years old	28 (19.7%)	18 (25.4%)	6 (11.5%)	8 (38.1%)	52 (12.1%)	7 (12.3%)	3 (9.1%)
Patients with chronic liver disease	12 (8.5%)	3 (4.2%)	0	1 (4.8%)	7 (1.6%)	3 (5.3%)	0
Patients with chronic cardiac disease and/or chronic lung disease	11 (7.7%)	4 (5.6%)	1 (1.9%)	1 (4.8%)	7 (1.6%)	2 (3.5%)	0
Patients with neoplasms or using immunosuppressive drugs	2 (1.4%)	1 (1.4%)	1 (1.9%)	0	6 (1.4%)	0	0
Patients with chronic kidney disease	7 (4.9%)	1 (1.4%)	0	1 (4.8%)	5 (1.2%)	2 (3.5%)	0
Patients with anatomical and functional asplenia	2 (1.4%)	1 (1.4%)	0	0	4 (0.9%)	1 (1.8%)	0
Patients with rheumatic disease	4 (2.8%)	0	0	2 (9.5%)	2 (0.5%)	2 (3.5%)	0
Patients with primary immunodeficiencies	4 (2.8%)	2 (2.8%)	0	0	7 (1.6%)	1 (1.8%)	0
Patients with HIV/AIDS	9 (6.3%)	3 (4.2%)	0	1 (4.8%)	8 (1.9%)	5 (8.8%)	0
Solid organ transplant candidates and recipients	7 (4.9%)	0	0	0	7 (1.6%)	3 (5.3%)	0
Patients with hematopoietic stem cell transplant	3 (2.1%)	0	0	0	3 (0.7%)	1 (1.8%)	0
Patients with diabetes mellitus	8 (5.6%)	4 (5.6%)	3 (5.8%)	1 (4.8%)	7 (1.6%)	1 (1.8%)	0
None of the above	13 (9.2%)	4 (5.6%)	3 (5.8%)	0	41 (9.5%)	1 (1.8%)	2 (6.1%)
Total score							
N	142	71	52	21	430	57	33
Mean	0.71	0.73	0.81	0.88	0.75	0.86	0.82
Standard deviation	0.41	0.39	0.36	0.31	0.36	0.31	0.30
Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Varicella, n (%)							
All patients (regardless of age and risk group)	19 (37.3%)	11 (26.2%)	6 (40.0%)	4 (44.4%)	39 (37.1%)	8 (18.2%)	6 (46.2%)
Adults - 20 to 59 years old	18 (35.3%)	19 (45.2%)	3 (20.0%)	2 (22.2%)	38 (36.2%)	21 (47.7%)	4 (30.8%)
Older adults - ≥ 60 years old	10 (19.6%)	7 (16.7%)	3 (20.0%)	0	11 (10.5%)	11 (25.0%)	4 (30.8%)
Patients with chronic liver disease	6 (11.8%)	5 (11.9%)	2 (13.3%)	0	3 (2.9%)	7 (15.9%)	0
Patients with chronic cardiac disease and/or chronic lung disease	9 (17.6%)	4 (9.5%)	2 (13.3%)	0	3 (2.9%)	5 (11.4%)	1 (7.7%)
Patients with neoplasms or using immunosuppressive drugs	4 (7.8%)	3 (7.1%)	2 (13.3%)	0	4 (3.8%)	4 (9.1%)	1 (7.7%)
Patients with chronic kidney disease	3 (5.9%)	3 (7.1%)	2 (13.3%)	0	4 (3.8%)	5 (11.4%)	0

Patients with anatomical and functional asplenia	5 (9.8%)	2 (4.8%)	3 (20.0%)	0	2 (1.9%)	3 (6.8%)	0
Patients with rheumatic disease	2 (3.9%)	3 (7.1%)	2 (13.3%)	0	6 (5.7%)	5 (11.4%)	0
Patients with primary immunodeficiencies	6 (11.8%)	2 (4.8%)	3 (20.0%)	0	6 (5.7%)	5 (11.4%)	0
Patients with HIV/AIDS	7 (13.7%)	2 (4.8%)	2 (13.3%)	0	6 (5.7%)	7 (15.9%)	0
Solid organ transplant candidates and recipients	4 (7.8%)	2 (4.8%)	3 (20.0%)	0	5 (4.8%)	6 (13.6%)	0
Patients with hematopoietic stem cell transplant	2 (3.9%)	1 (2.4%)	3 (20.0%)	0	5 (4.8%)	4 (9.1%)	0
Patients with diabetes mellitus	6 (11.8%)	3 (7.1%)	2 (13.3%)	0	3 (2.9%)	8 (18.2%)	0
None of the above	4 (7.8%)	8 (19.0%)	1 (6.7%)	3 (33.3%)	21 (20.0%)	5 (11.4%)	2 (15.4%)

Total score

N	51	42	15	9	105	44	13
Mean	0.42	0.42	0.38	0.22	0.35	0.53	0.08
Standard deviation	0.46	0.48	0.49	0.44	0.47	0.47	0.28
Median	0.00	0.00	0.00	0.00	0.00	0.76	0.00
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	1.00	1.00	1.00	1.00	1.00	1.00	1.00

Influenza, n (%)

All patients (regardless of age and risk group)	96 (40.2%)	32 (39.0%)	21 (27.3%)	10 (38.5%)	241 (48.9%)	39 (66.1%)	21 (36.2%)
Adults - 20 to 59 years old	24 (10.0%)	15 (18.3%)	9 (11.7%)	3 (11.5%)	75 (15.2%)	4 (6.8%)	5 (8.6%)
Older adults - ≥ 60 years old	137 (57.3%)	44 (53.7%)	53 (68.8%)	16 (61.5%)	225 (45.6%)	19 (32.2%)	36 (62.1%)
Patients with chronic liver disease	66 (27.6%)	20 (24.4%)	35 (45.5%)	5 (19.2%)	80 (16.2%)	16 (27.1%)	25 (43.1%)
Patients with chronic cardiac disease and/or chronic lung disease	106 (44.4%)	32 (39.0%)	38 (49.4%)	8 (30.8%)	119 (24.1%)	19 (32.2%)	36 (62.1%)
Patients with neoplasms or using immunosuppressive drugs	53 (22.2%)	12 (14.6%)	23 (29.9%)	3 (11.5%)	72 (14.6%)	14 (23.7%)	24 (41.4%)
Patients with chronic kidney disease	73 (30.5%)	19 (23.2%)	32 (41.6%)	7 (26.9%)	91 (18.5%)	18 (30.5%)	27 (46.6%)
Patients with anatomical and functional asplenia	41 (17.2%)	10 (12.2%)	21 (27.3%)	4 (15.4%)	57 (11.6%)	15 (25.4%)	21 (36.2%)
Patients with rheumatic disease	48 (20.1%)	16 (19.5%)	24 (31.2%)	6 (23.1%)	74 (15.0%)	16 (27.1%)	24 (41.4%)
Patients with primary immunodeficiencies	43 (18.0%)	15 (18.3%)	20 (26.0%)	4 (15.4%)	86 (17.4%)	14 (23.7%)	22 (37.9%)
Patients with HIV/AIDS	51 (21.3%)	18 (22.0%)	23 (29.9%)	5 (19.2%)	104 (21.1%)	19 (32.2%)	25 (43.1%)
Solid organ transplant candidates and recipients	46 (19.2%)	12 (14.6%)	18 (23.4%)	3 (11.5%)	63 (12.8%)	16 (27.1%)	23 (39.7%)
Patients with hematopoietic stem cell transplant	39 (16.3%)	12 (14.6%)	16 (20.8%)	3 (11.5%)	57 (11.6%)	14 (23.7%)	21 (36.2%)
Patients with diabetes mellitus	80 (33.5%)	28 (34.1%)	45 (58.4%)	8 (30.8%)	104 (21.1%)	18 (30.5%)	30 (51.7%)
None of the above	1 (0.4%)	2 (2.4%)	0	0	11 (2.2%)	0	0

Total score

N	239	82	77	26	493	59	58
Mean	0.66	0.63	0.63	0.61	0.68	0.92	0.79
Standard deviation	0.37	0.38	0.35	0.41	0.39	0.16	0.29
Median	0.85	0.77	0.69	0.81	0.92	1.00	0.92
Minimum	0.00	0.00	0.08	0.08	0.00	0.08	0.15
Maximum	1.00	1.00	1.00	1.00	1.00	1.00	1.00

Meningococcal Conjugate ACWY, n (%)

All patients (regardless of age and risk group)	20 (42.6%)	13 (31.7%)	5 (38.5%)	1 (25.0%)	24 (31.6%)	20 (44.4%)	10 (62.5%)
Adults - 20 to 59 years old	11 (23.4%)	9 (22.0%)	2 (15.4%)	2 (50.0%)	31 (40.8%)	9 (20.0%)	5 (31.3%)
Older adults - ≥ 60 years old	10 (21.3%)	10 (24.4%)	2 (15.4%)	0	16 (21.1%)	5 (11.1%)	3 (18.8%)
Patients with chronic liver disease	5 (10.6%)	7 (17.1%)	3 (23.1%)	0	3 (3.9%)	7 (15.6%)	0
Patients with chronic cardiac disease and/or chronic lung disease	12 (25.5%)	9 (22.0%)	4 (30.8%)	0	5 (6.6%)	8 (17.8%)	3 (18.8%)
Patients with neoplasms or using immunosuppressive drugs	3 (6.4%)	7 (17.1%)	2 (15.4%)	0	7 (9.2%)	7 (15.6%)	1 (6.3%)
Patients with chronic kidney disease	6 (12.8%)	6 (14.6%)	2 (15.4%)	0	4 (5.3%)	8 (17.8%)	1 (6.3%)
Patients with anatomical and functional asplenia	8 (17.0%)	5 (12.2%)	1 (7.7%)	0	4 (5.3%)	14 (31.1%)	0
Patients with rheumatic disease	4 (8.5%)	5 (12.2%)	2 (15.4%)	0	2 (2.6%)	10 (22.2%)	0
Patients with primary immunodeficiencies	7 (14.9%)	8 (19.5%)	3 (23.1%)	0	7 (9.2%)	12 (26.7%)	1 (6.3%)
Patients with HIV/AIDS	5 (10.6%)	8 (19.5%)	1 (7.7%)	0	9 (11.8%)	16 (35.6%)	0
Solid organ transplant candidates and recipients	4 (8.5%)	5 (12.2%)	2 (15.4%)	0	5 (6.6%)	12 (26.7%)	0
Patients with hematopoietic stem cell transplant	3 (6.4%)	6 (14.6%)	2 (15.4%)	0	5 (6.6%)	12 (26.7%)	0
Patients with diabetes mellitus	7 (14.9%)	5 (12.2%)	2 (15.4%)	0	1 (1.3%)	5 (11.1%)	0
None of the above	3 (6.4%)	6 (14.6%)	2 (15.4%)	1 (25.0%)	13 (17.1%)	4 (8.9%)	0
Total score							
N	47	41	13	4	76	45	16
Mean	0.09	0.14	0.11	0.05	0.10	0.20	0.05
Standard deviation	0.16	0.22	0.23	0.05	0.16	0.28	0.08
Median	0.00	0.00	0.00	0.05	0.09	0.00	0.00
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	0.73	0.73	0.82	0.09	0.73	0.82	0.27
Meningococcal B, n (%)							
All patients (regardless of age and risk group)	22 (48.9%)	17 (43.6%)	4 (33.3%)	0	21 (38.9%)	14 (40.0%)	8 (66.7%)
Adults - 20 to 59 years old	12 (26.7%)	9 (23.1%)	1 (8.3%)	2 (50.0%)	19 (35.2%)	12 (34.3%)	2 (16.7%)
Older adults - ≥ 60 years old	10 (22.2%)	6 (15.4%)	1 (8.3%)	1 (25.0%)	7 (13.0%)	5 (14.3%)	1 (8.3%)
Patients with chronic liver disease	4 (8.9%)	4 (10.3%)	2 (16.7%)	1 (25.0%)	3 (5.6%)	6 (17.1%)	1 (8.3%)
Patients with chronic cardiac disease and/or chronic lung disease	9 (20.0%)	4 (10.3%)	2 (16.7%)	1 (25.0%)	3 (5.6%)	7 (20.0%)	1 (8.3%)
Patients with neoplasms or using immunosuppressive drugs	5 (11.1%)	3 (7.7%)	1 (8.3%)	0	3 (5.6%)	6 (17.1%)	0
Patients with chronic kidney disease	4 (8.9%)	5 (12.8%)	1 (8.3%)	1 (25.0%)	2 (3.7%)	7 (20.0%)	0
Patients with anatomical and functional asplenia	6 (13.3%)	5 (12.8%)	0	1 (25.0%)	2 (3.7%)	9 (25.7%)	0
Patients with rheumatic disease	1 (2.2%)	3 (7.7%)	1 (8.3%)	0	2 (3.7%)	7 (20.0%)	0
Patients with primary immunodeficiencies	3 (6.7%)	6 (15.4%)	1 (8.3%)	0	4 (7.4%)	8 (22.9%)	0
Patients with HIV/AIDS	3 (6.7%)	6 (15.4%)	1 (8.3%)	1 (25.0%)	7 (13.0%)	8 (22.9%)	0
Solid organ transplant candidates and recipients	3 (6.7%)	2 (5.1%)	0	1 (25.0%)	3 (5.6%)	8 (22.9%)	0
Patients with hematopoietic stem cell transplant	3 (6.7%)	2 (5.1%)	0	0	2 (3.7%)	6 (17.1%)	0
Patients with diabetes mellitus	4 (8.9%)	4 (10.3%)	2 (16.7%)	1 (25.0%)	0	3 (8.6%)	0
None of the above	2 (4.4%)	4 (10.3%)	3 (25.0%)	1 (25.0%)	9 (16.7%)	2 (5.7%)	2 (16.7%)

Total score							
N	45	39	12	4	54	35	12
Mean	0.06	0.08	0.03	0.10	0.07	0.18	0.01
Standard deviation	0.14	0.17	0.07	0.14	0.16	0.27	0.03
Median	0.00	0.00	0.00	0.05	0.00	0.00	0.00
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	0.70	0.70	0.20	0.30	0.80	0.80	0.10
Yellow Fever, n (%)							
All patients (regardless of age and risk group)	66 (31.3%)	26 (33.3%)	14 (21.5%)	3 (12.5%)	163 (44.2%)	11 (18.6%)	11 (25.6%)
Adults - 20 to 59 years old	91 (43.1%)	39 (50.0%)	32 (49.2%)	9 (37.5%)	130 (35.2%)	41 (69.5%)	20 (46.5%)
Older adults - ≥ 60 years old	31 (14.7%)	20 (25.6%)	9 (13.8%)	2 (8.3%)	39 (10.6%)	11 (18.6%)	9 (20.9%)
Patients with chronic liver disease	9 (4.3%)	6 (7.7%)	2 (3.1%)	0	7 (1.9%)	5 (8.5%)	2 (4.7%)
Patients with chronic cardiac disease and/or chronic lung disease	19 (9.0%)	8 (10.3%)	2 (3.1%)	1 (4.2%)	13 (3.5%)	6 (10.2%)	3 (7.0%)
Patients with neoplasms or using immunosuppressive drugs	4 (1.9%)	4 (5.1%)	0	0	2 (0.5%)	1 (1.7%)	0
Patients with chronic kidney disease	10 (4.7%)	6 (7.7%)	1 (1.5%)	2 (8.3%)	7 (1.9%)	5 (8.5%)	2 (4.7%)
Patients with anatomical and functional asplenia	6 (2.8%)	1 (1.3%)	2 (3.1%)	0	4 (1.1%)	1 (1.7%)	1 (2.3%)
Patients with rheumatic disease	10 (4.7%)	3 (3.8%)	2 (3.1%)	1 (4.2%)	8 (2.2%)	3 (5.1%)	2 (4.7%)
Patients with primary immunodeficiencies	3 (1.4%)	1 (1.3%)	0	0	3 (0.8%)	0	0
Patients with HIV/AIDS	4 (1.9%)	4 (5.1%)	1 (1.5%)	0	3 (0.8%)	6 (10.2%)	0
Solid organ transplant candidates and recipients	6 (2.8%)	0	1 (1.5%)	1 (4.2%)	1 (0.3%)	2 (3.4%)	1 (2.3%)
Patients with hematopoietic stem cell transplant	3 (1.4%)	1 (1.3%)	0	0	1 (0.3%)	0	0
Patients with diabetes mellitus	24 (11.4%)	12 (15.4%)	5 (7.7%)	1 (4.2%)	17 (4.6%)	8 (13.6%)	3 (7.0%)
None of the above	46 (21.8%)	10 (12.8%)	18 (27.7%)	11 (45.8%)	70 (19.0%)	7 (11.9%)	11 (25.6%)
Total score							
N	211	78	65	24	369	59	43
Mean	0.19	0.27	0.25	0.22	0.19	0.32	0.27
Standard deviation	0.28	0.35	0.32	0.30	0.30	0.30	0.35
Median	0.00	0.00	0.00	0.00	0.00	0.50	0.00
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
PCV13, n (%)							
All patients (regardless of age and risk group)	46 (22.1%)	18 (26.5%)	10 (22.7%)	4 (16.0%)	46 (35.1%)	16 (34.0%)	13 (22.8%)
Adults - 20 to 59 years old	34 (16.3%)	15 (22.1%)	3 (6.8%)	5 (20.0%)	26 (19.8%)	3 (6.4%)	9 (15.8%)
Older adults - ≥ 60 years old	128 (61.5%)	39 (57.4%)	26 (59.1%)	17 (68.0%)	65 (49.6%)	22 (46.8%)	38 (66.7%)
Patients with chronic liver disease	48 (23.1%)	13 (19.1%)	10 (22.7%)	6 (24.0%)	15 (11.5%)	12 (25.5%)	21 (36.8%)
Patients with chronic cardiac disease and/or chronic lung disease	92 (44.2%)	24 (35.3%)	19 (43.2%)	13 (52.0%)	26 (19.8%)	19 (40.4%)	40 (70.2%)
Patients with neoplasms or using immunosuppressive drugs	36 (17.3%)	11 (16.2%)	13 (29.5%)	7 (28.0%)	17 (13.0%)	15 (31.9%)	17 (29.8%)
Patients with chronic kidney disease	49 (23.6%)	12 (17.6%)	12 (27.3%)	8 (32.0%)	11 (8.4%)	14 (29.8%)	23 (40.4%)

Patients with anatomical and functional asplenia	40 (19.2%)	12 (17.6%)	12 (27.3%)	7 (28.0%)	9 (6.9%)	17 (36.2%)	20 (35.1%)
Patients with rheumatic disease	35 (16.8%)	13 (19.1%)	6 (13.6%)	7 (28.0%)	10 (7.6%)	9 (19.1%)	20 (35.1%)
Patients with primary immunodeficiencies	36 (17.3%)	14 (20.6%)	13 (29.5%)	4 (16.0%)	16 (12.2%)	15 (31.9%)	17 (29.8%)
Patients with HIV/AIDS	42 (20.2%)	15 (22.1%)	12 (27.3%)	5 (20.0%)	22 (16.8%)	20 (42.6%)	18 (31.6%)
Solid organ transplant candidates and recipients	38 (18.3%)	14 (20.6%)	10 (22.7%)	4 (16.0%)	14 (10.7%)	14 (29.8%)	18 (31.6%)
Patients with hematopoietic stem cell transplant	33 (15.9%)	10 (14.7%)	9 (20.5%)	2 (8.0%)	13 (9.9%)	13 (27.7%)	16 (28.1%)
Patients with diabetes mellitus	42 (20.2%)	15 (22.1%)	16 (36.4%)	7 (28.0%)	11 (8.4%)	9 (19.1%)	24 (42.1%)
None of the above	8 (3.8%)	2 (2.9%)	4 (9.1%)	2 (8.0%)	11 (8.4%)	4 (8.5%)	3 (5.3%)

Total score

N	208	68	44	25	131	47	57
Mean	0.24	0.23	0.28	0.28	0.15	0.29	0.38
Standard deviation	0.28	0.29	0.31	0.31	0.24	0.35	0.36
Median	0.15	0.08	0.19	0.15	0.08	0.08	0.23
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	1.00	1.00	1.00	0.92	0.92	0.92	0.92

PPV23, n (%)

All patients (regardless of age and risk group)	44 (22.6%)	15 (22.7%)	9 (24.3%)	4 (15.4%)	46 (36.2%)	11 (19.0%)	13 (22.4%)
Adults - 20 to 59 years old	27 (13.8%)	17 (25.8%)	2 (5.4%)	3 (11.5%)	26 (20.5%)	10 (17.2%)	11 (19.0%)
Older adults - ≥ 60 years old	123 (63.1%)	39 (59.1%)	22 (59.5%)	18 (69.2%)	60 (47.2%)	40 (69.0%)	40 (69.0%)
Patients with chronic liver disease	40 (20.5%)	11 (16.7%)	10 (27.0%)	10 (38.5%)	13 (10.2%)	23 (39.7%)	22 (37.9%)
Patients with chronic cardiac disease and/or chronic lung disease	91 (46.7%)	26 (39.4%)	16 (43.2%)	15 (57.7%)	29 (22.8%)	33 (56.9%)	41 (70.7%)
Patients with neoplasms or using immunosuppressive drugs	37 (19.0%)	11 (16.7%)	11 (29.7%)	7 (26.9%)	16 (12.6%)	23 (39.7%)	16 (27.6%)
Patients with chronic kidney disease	42 (21.5%)	14 (21.2%)	11 (29.7%)	8 (30.8%)	11 (8.7%)	26 (44.8%)	22 (37.9%)
Patients with anatomical and functional asplenia	36 (18.5%)	12 (18.2%)	14 (37.8%)	9 (34.6%)	9 (7.1%)	32 (55.2%)	19 (32.8%)
Patients with rheumatic disease	34 (17.4%)	11 (16.7%)	7 (18.9%)	7 (26.9%)	9 (7.1%)	20 (34.5%)	18 (31.0%)
Patients with primary immunodeficiencies	33 (16.9%)	12 (18.2%)	10 (27.0%)	5 (19.2%)	13 (10.2%)	30 (51.7%)	15 (25.9%)
Patients with HIV/AIDS	38 (19.5%)	16 (24.2%)	10 (27.0%)	5 (19.2%)	18 (14.2%)	35 (60.3%)	17 (29.3%)
Solid organ transplant candidates and recipients	31 (15.9%)	11 (16.7%)	9 (24.3%)	5 (19.2%)	17 (13.4%)	25 (43.1%)	15 (25.9%)
Patients with hematopoietic stem cell transplant	25 (12.8%)	9 (13.6%)	9 (24.3%)	4 (15.4%)	10 (7.9%)	23 (39.7%)	18 (31.0%)
Patients with diabetes mellitus	40 (20.5%)	14 (21.2%)	15 (40.5%)	11 (42.3%)	13 (10.2%)	22 (37.9%)	22 (37.9%)
None of the above	5 (2.6%)	1 (1.5%)	3 (8.1%)	0	11 (8.7%)	2 (3.4%)	0

Total score

N	195	66	37	26	127	58	58
Mean	0.23	0.23	0.30	0.32	0.14	0.45	0.37
Standard deviation	0.28	0.29	0.34	0.31	0.23	0.38	0.36
Median	0.15	0.12	0.15	0.23	0.08	0.42	0.23
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	1.00	0.92	1.00	0.92	0.92	1.00	1.00

Zoster, n (%)

All patients (regardless of age and risk group)	22 (24.7%)	9 (17.6%)	2 (6.5%)	2 (8.7%)	24 (7.8%)	4 (9.8%)	6 (31.6%)
Adults - 20 to 59 years old	19 (21.3%)	18 (35.3%)	3 (9.7%)	1 (4.3%)	88 (28.6%)	7 (17.1%)	4 (21.1%)
Older adults - ≥ 60 years old	51 (57.3%)	26 (51.0%)	24 (77.4%)	16 (69.6%)	222 (72.1%)	32 (78.0%)	11 (57.9%)
Patients with chronic liver disease	8 (9.0%)	2 (3.9%)	4 (12.9%)	4 (17.4%)	6 (1.9%)	5 (12.2%)	1 (5.3%)
Patients with chronic cardiac disease and/or chronic lung disease	16 (18.0%)	2 (3.9%)	5 (16.1%)	3 (13.0%)	30 (9.7%)	2 (4.9%)	1 (5.3%)
Patients with neoplasms or using immunosuppressive drugs	8 (9.0%)	2 (3.9%)	6 (19.4%)	3 (13.0%)	43 (14.0%)	1 (2.4%)	1 (5.3%)
Patients with chronic kidney disease	7 (7.9%)	2 (3.9%)	3 (9.7%)	5 (21.7%)	13 (4.2%)	3 (7.3%)	1 (5.3%)
Patients with anatomical and functional asplenia	3 (3.4%)	3 (5.9%)	5 (16.1%)	3 (13.0%)	9 (2.9%)	2 (4.9%)	1 (5.3%)
Patients with rheumatic disease	9 (10.1%)	2 (3.9%)	5 (16.1%)	5 (21.7%)	21 (6.8%)	3 (7.3%)	1 (5.3%)
Patients with primary immunodeficiencies	11 (12.4%)	2 (3.9%)	6 (19.4%)	4 (17.4%)	40 (13.0%)	1 (2.4%)	1 (5.3%)
Patients with HIV/AIDS	9 (10.1%)	4 (7.8%)	6 (19.4%)	4 (17.4%)	48 (15.6%)	1 (2.4%)	1 (5.3%)
Solid organ transplant candidates and recipients	8 (9.0%)	5 (9.8%)	6 (19.4%)	1 (4.3%)	17 (5.5%)	2 (4.9%)	1 (5.3%)
Patients with hematopoietic stem cell transplant	6 (6.7%)	2 (3.9%)	5 (16.1%)	2 (8.7%)	14 (4.5%)	1 (2.4%)	1 (5.3%)
Patients with diabetes mellitus	12 (13.5%)	4 (7.8%)	9 (29.0%)	3 (13.0%)	37 (12.0%)	5 (12.2%)	1 (5.3%)
None of the above	7 (7.9%)	2 (3.9%)	2 (6.5%)	4 (17.4%)	26 (8.4%)	3 (7.3%)	2 (10.5%)
Total score							
N	89	51	31	23	308	41	19
Mean	0.29	0.29	0.31	0.36	0.33	0.40	0.31
Standard deviation	0.28	0.25	0.26	0.28	0.24	0.21	0.29
Median	0.25	0.29	0.50	0.50	0.50	0.50	0.50
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	1.00	0.80	0.75	0.71	0.75	0.71	0.67
Dengue, n (%)							
All patients (regardless of age and risk group)	37 (67.3%)	17 (56.7%)	7 (58.3%)	2 (66.7%)	48 (51.6%)	3 (25.0%)	6 (75.0%)
Adults - 20 to 59 years old	12 (21.8%)	12 (40.0%)	2 (16.7%)	1 (33.3%)	22 (23.7%)	4 (33.3%)	2 (25.0%)
Older adults - ≥ 60 years old	4 (7.3%)	7 (23.3%)	2 (16.7%)	0	9 (9.7%)	0	0
Patients with chronic liver disease	1 (1.8%)	2 (6.7%)	1 (8.3%)	0	3 (3.2%)	0	0
Patients with chronic cardiac disease and/or chronic lung disease	1 (1.8%)	2 (6.7%)	1 (8.3%)	0	3 (3.2%)	0	0
Patients with neoplasms or using immunosuppressive drugs	0	0	0	0	1 (1.1%)	0	0
Patients with chronic kidney disease	0	1 (3.3%)	0	0	1 (1.1%)	0	0
Patients with anatomical and functional asplenia	1 (1.8%)	1 (3.3%)	0	0	1 (1.1%)	0	0
Patients with rheumatic disease	0	1 (3.3%)	0	0	1 (1.1%)	0	0
Patients with primary immunodeficiencies	0	0	0	0	0	0	0
Patients with HIV/AIDS	0	0	1 (8.3%)	0	1 (1.1%)	0	0
Solid organ transplant candidates and recipients	0	0	0	0	0	0	0
Patients with hematopoietic stem cell transplant	0	0	0	0	0	0	0
Patients with diabetes mellitus	3 (5.5%)	4 (13.3%)	1 (8.3%)	0	2 (2.2%)	0	0
None of the above	5 (9.1%)	1 (3.3%)	3 (25.0%)	0	20 (21.5%)	5 (41.7%)	0

Total score							
N	55	30	12	3	93	12	8
Mean	0.22	0.17	0.25	0.33	0.38	0.75	0.25
Standard deviation	0.42	0.38	0.45	0.58	0.49	0.45	0.46
Median	0.00	0.00	0.00	0.00	0.00	1.00	0.00
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Bivalent HPV, n (%)							
All patients (regardless of age and risk group)	15 (39.5%)	8 (18.2%)	2 (9.5%)	1 (33.3%)	56 (16.1%)	7 (20.6%)	3 (27.3%)
Adults - 20 to 59 years old	11 (28.9%)	18 (40.9%)	7 (33.3%)	2 (66.7%)	150 (43.1%)	12 (35.3%)	4 (36.4%)
Older adults - ≥ 60 years old	1 (2.6%)	3 (6.8%)	1 (4.8%)	0	33 (9.5%)	1 (2.9%)	0
Patients with chronic liver disease	1 (2.6%)	0	1 (4.8%)	0	4 (1.1%)	0	0
Patients with chronic cardiac disease and/or chronic lung disease	2 (5.3%)	0	0	0	2 (0.6%)	0	1 (9.1%)
Patients with neoplasms or using immunosuppressive drugs	1 (2.6%)	2 (4.5%)	0	0	9 (2.6%)	0	0
Patients with chronic kidney disease	0	0	0	0	6 (1.7%)	0	0
Patients with anatomical and functional asplenia	1 (2.6%)	1 (2.3%)	0	0	3 (0.9%)	0	0
Patients with rheumatic disease	1 (2.6%)	1 (2.3%)	1 (4.8%)	0	9 (2.6%)	0	0
Patients with primary immunodeficiencies	2 (5.3%)	1 (2.3%)	2 (9.5%)	0	14 (4.0%)	2 (5.9%)	0
Patients with HIV/AIDS	1 (2.6%)	1 (2.3%)	2 (9.5%)	0	50 (14.4%)	5 (14.7%)	1 (9.1%)
Solid organ transplant candidates and recipients	0	1 (2.3%)	1 (4.8%)	0	9 (2.6%)	1 (2.9%)	0
Patients with hematopoietic stem cell transplant	0	1 (2.3%)	1 (4.8%)	0	8 (2.3%)	1 (2.9%)	0
Patients with diabetes mellitus	4 (10.5%)	3 (6.8%)	0	0	7 (2.0%)	0	0
None of the above	11 (28.9%)	16 (36.4%)	12 (57.1%)	0	126 (36.2%)	13 (38.2%)	4 (36.4%)
Total score							
N	38	44	21	3	348	34	11
Mean	0.07	0.07	0.11	0.17	0.11	0.12	0.09
Standard deviation	0.15	0.12	0.23	0.14	0.15	0.18	0.13
Median	0.00	0.00	0.00	0.25	0.00	0.00	0.00
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	0.75	0.25	1.00	0.25	0.75	0.50	0.25
Quadrivalent HPV, n (%)							
All patients (regardless of age and risk group)	8 (21.6%)	8 (22.9%)	2 (11.8%)	1 (20.0%)	86 (17.5%)	12 (26.7%)	4 (50.0%)
Adults - 20 to 59 years old	15 (40.5%)	15 (42.9%)	2 (11.8%)	2 (40.0%)	172 (35.0%)	17 (37.8%)	1 (12.5%)
Older adults - ≥ 60 years old	2 (5.4%)	3 (8.6%)	0	0	34 (6.9%)	1 (2.2%)	0
Patients with chronic liver disease	0	0	0	0	3 (0.6%)	0	0
Patients with chronic cardiac disease and/or chronic lung disease	1 (2.7%)	0	0	0	4 (0.8%)	0	0
Patients with neoplasms or using immunosuppressive drugs	1 (2.7%)	1 (2.9%)	0	0	13 (2.6%)	1 (2.2%)	0
Patients with chronic kidney disease	0	0	0	0	5 (1.0%)	0	0

Patients with anatomical and functional asplenia	0	0	1 (5.9%)	0	3 (0.6%)	0	0
Patients with rheumatic disease	3 (8.1%)	0	1 (5.9%)	0	5 (1.0%)	0	0
Patients with primary immunodeficiencies	1 (2.7%)	1 (2.9%)	1 (5.9%)	0	20 (4.1%)	1 (2.2%)	0
Patients with HIV/AIDS	2 (5.4%)	2 (5.7%)	1 (5.9%)	0	72 (14.7%)	16 (35.6%)	0
Solid organ transplant candidates and recipients	2 (5.4%)	0	1 (5.9%)	0	20 (4.1%)	1 (2.2%)	0
Patients with hematopoietic stem cell transplant	1 (2.7%)	0	1 (5.9%)	0	16 (3.3%)	1 (2.2%)	0
Patients with diabetes mellitus	4 (10.8%)	2 (5.7%)	0	0	8 (1.6%)	0	0
None of the above	12 (32.4%)	10 (28.6%)	12 (70.6%)	2 (40.0%)	200 (40.7%)	11 (24.4%)	3 (37.5%)

Total score

N	37	35	17	5	491	45	8
Mean	0.09	0.10	0.03	0.10	0.10	0.17	0.03
Standard deviation	0.12	0.14	0.08	0.14	0.15	0.21	0.09
Median	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Minimum	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Maximum	0.25	0.50	0.25	0.25	0.75	0.50	0.25

Note: Proportions were determined based on the number of physicians of each medical specialty who stated to prescribe each vaccine to adult and/or older adult patients.

Supplementary Table 11 – Knowledge of vaccines – Dosage schedule in accordance with the recommendations of the Brazilian Society of Immunization by medical specialties

	Cardiology (n=244)	General Practice/Family Practice (n=85)	Endocrinology (n=80)	Geriatrics (n=26)	Gynecology (n=515)	Infectious Diseases (n=59)	Pulmonology (n=59)
MMR, n (%)							
Single dose	17 (19.1%)	15 (25.4%)	11 (36.7%)	5 (62.5%)	90 (28.9%)	17 (30.9%)	6 (22.2%)
Single dose – the need for additional doses depends on the epidemiological situation	23 (25.8%)	17 (28.8%)	7 (23.3%)	1 (12.5%)	54 (17.4%)	8 (14.5%)	8 (29.6%)
Single annual dose	1 (1.1%)	0	0	0	4 (1.3%)	0	0
Two doses	18 (20.2%)	15 (25.4%)	9 (30.0%)	2 (25.0%)	92 (29.6%)	25 (45.5%)	4 (14.8%)
Three doses	6 (6.7%)	5 (8.5%)	1 (3.3%)	0	31 (10.0%)	1 (1.8%)	5 (18.5%)
Booster dose every 10 years	13 (14.6%)	3 (5.1%)	1 (3.3%)	0	18 (5.8%)	2 (3.6%)	2 (7.4%)
Sequential schedule with two vaccines (total of three doses)	3 (3.4%)	4 (6.8%)	1 (3.3%)	0	11 (3.5%)	1 (1.8%)	1 (3.7%)
No need for additional doses	4 (4.5%)	0	0	0	1 (0.3%)	0	1 (3.7%)
None of the above	4 (4.5%)	0	0	0	10 (3.2%)	1 (1.8%)	0
Total	89	59	30	8	311	55	27
Hepatitis A, n (%)							
Single dose	27 (32.5%)	13 (27.7%)	10 (32.3%)	2 (18.2%)	49 (32.5%)	8 (14.5%)	7 (38.9%)
Single dose – the need for additional doses depends on the epidemiological situation	13 (15.7%)	7 (14.9%)	4 (12.9%)	2 (18.2%)	20 (13.2%)	3 (5.5%)	3 (16.7%)
Single annual dose	0	2 (4.3%)	1 (3.2%)	0	1 (0.7%)	0	0
Two doses	20 (24.1%)	17 (36.2%)	12 (38.7%)	4 (36.4%)	37 (24.5%)	43 (78.2%)	5 (27.8%)
Three doses	12 (14.5%)	3 (6.4%)	0	3 (27.3%)	25 (16.6%)	0	1 (5.6%)
Booster dose every 10 years	1 (1.2%)	3 (6.4%)	1 (3.2%)	0	2 (1.3%)	0	0
Sequential schedule with two vaccines (total of three doses)	6 (7.2%)	0	3 (9.7%)	0	7 (4.6%)	0	0
No need for additional doses	1 (1.2%)	1 (2.1%)	0	0	2 (1.3%)	0	1 (5.6%)
None of the above	3 (3.6%)	1 (2.1%)	0	0	8 (5.3%)	1 (1.8%)	1 (5.6%)
Total	83	47	31	11	151	55	18
Hepatitis B, n (%)							
Single dose	13 (7.0%)	5 (6.7%)	3 (4.6%)	0	31 (6.3%)	1 (1.7%)	2 (5.4%)
Single dose – the need for additional doses depends on the epidemiological situation	10 (5.3%)	3 (4.0%)	0	1 (4.3%)	9 (1.8%)	0	3 (8.1%)
Single annual dose	1 (0.5%)	1 (1.3%)	0	0	1 (0.2%)	0	0
Two doses	13 (7.0%)	2 (2.7%)	2 (3.1%)	1 (4.3%)	11 (2.2%)	1 (1.7%)	3 (8.1%)
Three doses	122 (65.2%)	55 (73.3%)	50 (76.9%)	18 (78.3%)	395 (80.8%)	54 (91.5%)	24 (64.9%)
Booster dose every 10 years	8 (4.3%)	3 (4.0%)	3 (4.6%)	0	6 (1.2%)	0	0

	Cardiology (n=244)	General Practice/Family Practice (n=85)	Endocrinology (n=80)	Geriatrics (n=26)	Gynecology (n=515)	Infectious Diseases (n=59)	Pulmonology (n=59)
Sequential schedule with two vaccines (total of three doses)	17 (9.1%)	5 (6.7%)	7 (10.8%)	3 (13.0%)	30 (6.1%)	1 (1.7%)	4 (10.8%)
No need for additional doses	1 (0.5%)	1 (1.3%)	0	0	3 (0.6%)	0	1 (2.7%)
None of the above	2 (1.1%)	0	0	0	3 (0.6%)	2 (3.4%)	0
Total	187	75	65	23	489	59	37
Hepatitis A and B, n (%)							
Single dose	9 (8.8%)	9 (16.7%)	2 (4.9%)	1 (8.3%)	18 (7.4%)	5 (12.2%)	2 (9.1%)
Single dose – the need for additional doses depends on the epidemiological situation	16 (15.7%)	3 (5.6%)	1 (2.4%)	0	12 (4.9%)	0	3 (13.6%)
Single annual dose	2 (2.0%)	0	0	0	1 (0.4%)	0	0
Two doses	9 (8.8%)	6 (11.1%)	5 (12.2%)	0	20 (8.2%)	5 (12.2%)	1 (4.5%)
Three doses	39 (38.2%)	25 (46.3%)	18 (43.9%)	7 (58.3%)	132 (54.1%)	22 (53.7%)	12 (54.5%)
Booster dose every 10 years	9 (8.8%)	3 (5.6%)	1 (2.4%)	0	3 (1.2%)	0	0
Sequential schedule with two vaccines (total of three doses)	8 (7.8%)	2 (3.7%)	10 (24.4%)	3 (25.0%)	33 (13.5%)	6 (14.6%)	1 (4.5%)
No need for additional doses	1 (1.0%)	1 (1.9%)	0	0	2 (0.8%)	0	1 (4.5%)
None of the above	9 (8.8%)	5 (9.3%)	4 (9.8%)	1 (8.3%)	23 (9.4%)	3 (7.3%)	2 (9.1%)
Total	102	54	41	12	244	41	22
Tdap or Tdap-IPV, n (%)							
Single dose	21 (19.6%)	13 (21.0%)	11 (26.2%)	4 (20.0%)	129 (29.3%)	14 (24.1%)	10 (31.3%)
Single dose – the need for additional doses depends on the epidemiological situation	20 (18.7%)	7 (11.3%)	2 (4.8%)	4 (20.0%)	56 (12.7%)	5 (8.6%)	5 (15.6%)
Single annual dose	0	0	0	0	5 (1.1%)	0	0
Two doses	7 (6.5%)	2 (3.2%)	3 (7.1%)	1 (5.0%)	8 (1.8%)	0	4 (12.5%)
Three doses	9 (8.4%)	10 (16.1%)	0	1 (5.0%)	66 (15.0%)	5 (8.6%)	2 (6.3%)
Booster dose every 10 years	41 (38.3%)	21 (33.9%)	21 (50.0%)	7 (35.0%)	153 (34.8%)	31 (53.4%)	9 (28.1%)
Sequential schedule with two vaccines (total of three doses)	1 (0.9%)	3 (4.8%)	1 (2.4%)	0	10 (2.3%)	1 (1.7%)	0
No need for additional doses	2 (1.9%)	1 (1.6%)	1 (2.4%)	0	3 (0.7%)	1 (1.7%)	1 (3.1%)
None of the above	6 (5.6%)	5 (8.1%)	3 (7.1%)	3 (15.0%)	10 (2.3%)	1 (1.7%)	1 (3.1%)
Total	107	62	42	20	440	58	32
Tetanus and diphtheria, n (%)							
Single dose	17 (12.0%)	8 (11.3%)	8 (15.4%)	1 (4.8%)	47 (10.9%)	2 (3.5%)	6 (18.2%)
Single dose – the need for additional doses depends on the epidemiological situation	19 (13.4%)	7 (9.9%)	3 (5.8%)	2 (9.5%)	19 (4.4%)	2 (3.5%)	4 (12.1%)
Single annual dose	2 (1.4%)	1 (1.4%)	0	0	2 (0.5%)	0	0
Two doses	8 (5.6%)	6 (8.5%)	0	0	11 (2.6%)	1 (1.8%)	0
Three doses	7 (4.9%)	7 (9.9%)	0	2 (9.5%)	50 (11.6%)	1 (1.8%)	3 (9.1%)
Booster dose every 10 years	81 (57.0%)	40 (56.3%)	40 (76.9%)	15 (71.4%)	281 (65.3%)	48 (84.2%)	18 (54.5%)

	Cardiology (n=244)	General Practice/Family Practice (n=85)	Endocrinology (n=80)	Geriatrics (n=26)	Gynecology (n=515)	Infectious Diseases (n=59)	Pulmonology (n=59)
Sequential schedule with two vaccines (total of three doses)	1 (0.7%)	0	1 (1.9%)	0	3 (0.7%)	0	1 (3.0%)
No need for additional doses	1 (0.7%)	0	0	0	3 (0.7%)	1 (1.8%)	1 (3.0%)
None of the above	6 (4.2%)	2 (2.8%)	0	1 (4.8%)	14 (3.3%)	2 (3.5%)	0
Total	142	71	52	21	430	57	33
Varicella, n (%)^{a)}							
Single dose	23 (45.1%)	16 (38.1%)	10 (66.7%)	5 (55.6%)	48 (45.7%)	16 (36.4%)	6 (46.2%)
Single dose – the need for additional doses depends on the epidemiological situation	12 (23.5%)	5 (11.9%)	0	0	14 (13.3%)	2 (4.5%)	2 (15.4%)
Single annual dose	2 (3.9%)	2 (4.8%)	0	0	0	0	0
Two doses	7 (13.7%)	15 (35.7%)	5 (33.3%)	2 (22.2%)	34 (32.4%)	24 (54.5%)	2 (15.4%)
Three doses	0	2 (4.8%)	0	0	5 (4.8%)	0	1 (7.7%)
Booster dose every 10 years	4 (7.8%)	0	0	0	1 (1.0%)	0	0
Sequential schedule with two vaccines (total of three doses)	1 (2.0%)	0	0	0	1 (1.0%)	0	0
No need for additional doses	1 (2.0%)	0	0	1 (11.1%)	1 (1.0%)	1 (2.3%)	1 (7.7%)
None of the above	1 (2.0%)	2 (4.8%)	0	1 (11.1%)	1 (1.0%)	1 (2.3%)	1 (7.7%)
Total	51	42	15	9	105	44	13
Influenza, n (%)							
Single dose	31 (13.0%)	8 (9.8%)	7 (9.1%)	2 (7.7%)	84 (17.0%)	1 (1.7%)	10 (17.2%)
Single dose – the need for additional doses depends on the epidemiological situation	18 (7.5%)	0	3 (3.9%)	0	35 (7.1%)	2 (3.4%)	4 (6.9%)
Single annual dose	186 (77.8%)	74 (90.2%)	67 (87.0%)	24 (92.3%)	363 (73.6%)	55 (93.2%)	44 (75.9%)
Two doses	1 (0.4%)	0	0	0	3 (0.6%)	0	0
Three doses	0	0	0	0	0	0	0
Booster dose every 10 years	1 (0.4%)	0	0	0	1 (0.2%)	0	0
Sequential schedule with two vaccines (total of three doses)	0	0	0	0	1 (0.2%)	0	0
No need for additional doses	0	0	0	0	1 (0.2%)	0	0
None of the above	2 (0.8%)	0	0	0	5 (1.0%)	1 (1.7%)	0
Total	239	82	77	26	493	59	58
Meningococcal Conjugate ACWY, n (%)							
Single dose	14 (29.8%)	16 (39.0%)	10 (76.9%)	0	37 (48.7%)	18 (40.0%)	7 (43.8%)
Single dose – the need for additional doses depends on the epidemiological situation	13 (27.7%)	7 (17.1%)	1 (7.7%)	1 (25.0%)	14 (18.4%)	5 (11.1%)	4 (25.0%)
Single annual dose	7 (14.9%)	3 (7.3%)	0	0	6 (7.9%)	0	0
Two doses	6 (12.8%)	5 (12.2%)	1 (7.7%)	1 (25.0%)	10 (13.2%)	11 (24.4%)	3 (18.8%)
Three doses	1 (2.1%)	4 (9.8%)	0	0	3 (3.9%)	6 (13.3%)	0
Booster dose every 10 years	2 (4.3%)	4 (9.8%)	1 (7.7%)	0	2 (2.6%)	1 (2.2%)	1 (6.3%)

	Cardiology (n=244)	General Practice/Family Practice (n=85)	Endocrinology (n=80)	Geriatrics (n=26)	Gynecology (n=515)	Infectious Diseases (n=59)	Pulmonology (n=59)
Sequential schedule with two vaccines (total of three doses)	0	1 (2.4%)	0	0	1 (1.3%)	2 (4.4%)	0
No need for additional doses	0	0	0	0	0	0	1 (6.3%)
None of the above	4 (8.5%)	1 (2.4%)	0	2 (50.0%)	3 (3.9%)	2 (4.4%)	0
Total	47	41	13	4	76	45	16
Meningococcal B, n (%)^{a)}							
Single dose	14 (31.1%)	13 (33.3%)	6 (50.0%)	1 (25.0%)	15 (27.8%)	5 (14.3%)	4 (33.3%)
Single dose – the need for additional doses depends on the epidemiological situation	14 (31.1%)	6 (15.4%)	0	1 (25.0%)	13 (24.1%)	3 (8.6%)	3 (25.0%)
Single annual dose	5 (11.1%)	1 (2.6%)	0	0	5 (9.3%)	0	0
Two doses	5 (11.1%)	10 (25.6%)	4 (33.3%)	0	14 (25.9%)	18 (51.4%)	3 (25.0%)
Three doses	0	3 (7.7%)	0	0	3 (5.6%)	5 (14.3%)	1 (8.3%)
Booster dose every 10 years	4 (8.9%)	4 (10.3%)	1 (8.3%)	0	1 (1.9%)	2 (5.7%)	0
Sequential schedule with two vaccines (total of three doses)	0	2 (5.1%)	0	0	0	1 (2.9%)	0
No need for additional doses	0	0	0	1 (25.0%)	0	0	1 (8.3%)
None of the above	3 (6.7%)	0	1 (8.3%)	1 (25.0%)	3 (5.6%)	1 (2.9%)	0
Total	45	39	12	4	54	35	12
Yellow Fever, n (%)							
Single dose	106 (50.2%)	47 (60.3%)	43 (66.2%)	11 (45.8%)	203 (55.0%)	49 (83.1%)	30 (69.8%)
Single dose – the need for additional doses depends on the epidemiological situation	58 (27.5%)	10 (12.8%)	10 (15.4%)	6 (25.0%)	84 (22.8%)	6 (10.2%)	5 (11.6%)
Single annual dose	2 (0.9%)	1 (1.3%)	0	0	2 (0.5%)	0	0
Two doses	2 (0.9%)	3 (3.8%)	0	1 (4.2%)	9 (2.4%)	3 (5.1%)	0
Three doses	1 (0.5%)	0	0	0	1 (0.3%)	0	0
Booster dose every 10 years	35 (16.6%)	16 (20.5%)	12 (18.5%)	6 (25.0%)	62 (16.8%)	0	7 (16.3%)
Sequential schedule with two vaccines (total of three doses)	1 (0.5%)	0	0	0	0	0	0
No need for additional doses	4 (1.9%)	1 (1.3%)	0	0	4 (1.1%)	1 (1.7%)	0
None of the above	2 (0.9%)	0	0	0	4 (1.1%)	0	1 (2.3%)
Total	211	78	65	24	369	59	43
PCV13, n (%)^{b)}							
Single dose	95 (48.0%)	31 (48.4%)	24 (61.5%)	17 (68.0%)	68 (59.1%)	29 (70.7%)	42 (77.8%)
Single dose – the need for additional doses depends on the epidemiological situation	21 (10.6%)	6 (9.4%)	2 (5.1%)	3 (12.0%)	10 (8.7%)	2 (4.9%)	4 (7.4%)
Single annual dose	44 (22.2%)	17 (26.6%)	5 (12.8%)	1 (4.0%)	13 (11.3%)	1 (2.4%)	0
Two doses	14 (7.1%)	2 (3.1%)	2 (5.1%)	1 (4.0%)	8 (7.0%)	4 (9.8%)	2 (3.7%)
Three doses	2 (1.0%)	1 (1.6%)	1 (2.6%)	0	4 (3.5%)	0	1 (1.9%)
Booster dose every 10 years	12 (6.1%)	2 (3.1%)	2 (5.1%)	2 (8.0%)	2 (1.7%)	2 (4.9%)	3 (5.6%)

	Cardiology (n=244)	General Practice/Family Practice (n=85)	Endocrinology (n=80)	Geriatrics (n=26)	Gynecology (n=515)	Infectious Diseases (n=59)	Pulmonology (n=59)
Sequential schedule with two vaccines (total of three doses)	1 (0.5%)	2 (3.1%)	1 (2.6%)	0	4 (3.5%)	1 (2.4%)	1 (1.9%)
No need for additional doses	0	0	0	0	0	0	1 (1.9%)
None of the above	9 (4.5%)	3 (4.7%)	2 (5.1%)	1 (4.0%)	6 (5.2%)	2 (4.9%)	0
Total	198	64	39	25	115	41	54
PPV23, n (%)^{b)}							
Single dose	83 (43.9%)	25 (39.7%)	15 (44.1%)	8 (30.8%)	69 (59.0%)	20 (35.1%)	22 (37.9%)
Single dose – the need for additional doses depends on the epidemiological situation	20 (10.6%)	4 (6.3%)	3 (8.8%)	4 (15.4%)	13 (11.1%)	4 (7.0%)	5 (8.6%)
Single annual dose	43 (22.8%)	15 (23.8%)	3 (8.8%)	1 (3.8%)	11 (9.4%)	0	0
Two doses	13 (6.9%)	8 (12.7%)	3 (8.8%)	9 (34.6%)	12 (10.3%)	23 (40.4%)	10 (17.2%)
Three doses	1 (0.5%)	1 (1.6%)	1 (2.9%)	0	4 (3.4%)	0	1 (1.7%)
Booster dose every 10 years	13 (6.9%)	4 (6.3%)	3 (8.8%)	1 (3.8%)	1 (0.9%)	3 (5.3%)	4 (6.9%)
Sequential schedule with two vaccines (total of three doses)	6 (3.2%)	2 (3.2%)	2 (5.9%)	1 (3.8%)	2 (1.7%)	2 (3.5%)	3 (5.2%)
No need for additional doses	3 (1.6%)	0	0	0	0	0	0
None of the above	7 (3.7%)	4 (6.3%)	4 (11.8%)	2 (7.7%)	5 (4.3%)	5 (8.8%)	13 (22.4%)
Total	189	63	34	26	117	57	58
Zoster, n (%)							
Single dose	63 (70.8%)	36 (70.6%)	27 (87.1%)	20 (87.0%)	260 (84.4%)	32 (78.0%)	13 (68.4%)
Single dose – the need for additional doses depends on the epidemiological situation	6 (6.7%)	5 (9.8%)	0	0	5 (1.6%)	0	3 (15.8%)
Single annual dose	4 (4.5%)	0	0	1 (4.3%)	2 (0.6%)	0	0
Two doses	6 (6.7%)	4 (7.8%)	3 (9.7%)	2 (8.7%)	15 (4.9%)	8 (19.5%)	0
Three doses	1 (1.1%)	3 (5.9%)	0	0	12 (3.9%)	0	1 (5.3%)
Booster dose every 10 years	3 (3.4%)	2 (3.9%)	0	0	3 (1.0%)	1 (2.4%)	0
Sequential schedule with two vaccines (total of three doses)	2 (2.2%)	0	0	0	1 (0.3%)	0	0
No need for additional doses	2 (2.2%)	0	0	0	1 (0.3%)	0	0
None of the above	2 (2.2%)	1 (2.0%)	1 (3.2%)	0	9 (2.9%)	0	2 (10.5%)
Total	89	51	31	23	308	41	19
Dengue, n (%)^{a)}							
Single dose	18 (32.7%)	10 (33.3%)	9 (75.0%)	1 (33.3%)	37 (39.8%)	2 (16.7%)	2 (25.0%)
Single dose – the need for additional doses depends on the epidemiological situation	22 (40.0%)	11 (36.7%)	0	1 (33.3%)	22 (23.7%)	0	1 (12.5%)
Single annual dose	3 (5.5%)	1 (3.3%)	0	0	5 (5.4%)	1 (8.3%)	1 (12.5%)
Two doses	1 (1.8%)	1 (3.3%)	0	0	4 (4.3%)	1 (8.3%)	0
Three doses	7 (12.7%)	4 (13.3%)	2 (16.7%)	1 (33.3%)	15 (16.1%)	7 (58.3%)	2 (25.0%)
Booster dose every 10 years	2 (3.6%)	0	0	0	0	0	0

	Cardiology (n=244)	General Practice/Family Practice (n=85)	Endocrinology (n=80)	Geriatrics (n=26)	Gynecology (n=515)	Infectious Diseases (n=59)	Pulmonology (n=59)
Sequential schedule with two vaccines (total of three doses)	1 (1.8%)	2 (6.7%)	0	0	1 (1.1%)	0	0
No need for additional doses	0	0	0	0	1 (1.1%)	0	0
None of the above	1 (1.8%)	1 (3.3%)	1 (8.3%)	0	8 (8.6%)	1 (8.3%)	2 (25.0%)
Total	55	30	12	3	93	12	8
Bivalent HPV, n (%)^{a)}							
Single dose	18 (47.4%)	13 (29.5%)	4 (19.0%)	1 (33.3%)	19 (5.5%)	2 (5.9%)	1 (9.1%)
Single dose – the need for additional doses depends on the epidemiological situation	4 (10.5%)	3 (6.8%)	0	0	3 (0.9%)	0	0
Single annual dose	0	0	0	0	1 (0.3%)	0	0
Two doses	6 (15.8%)	10 (22.7%)	8 (38.1%)	0	65 (18.7%)	10 (29.4%)	4 (36.4%)
Three doses	5 (13.2%)	13 (29.5%)	7 (33.3%)	2 (66.7%)	228 (65.5%)	19 (55.9%)	4 (36.4%)
Booster dose every 10 years	0	1 (2.3%)	0	0	0	0	0
Sequential schedule with two vaccines (total of three doses)	1 (2.6%)	1 (2.3%)	1 (4.8%)	0	20 (5.7%)	0	1 (9.1%)
No need for additional doses	1 (2.6%)	0	0	0	1 (0.3%)	0	0
None of the above	3 (7.9%)	3 (6.8%)	1 (4.8%)	0	11 (3.2%)	3 (8.8%)	1 (9.1%)
Total	38	44	21	3	348	34	11
Quadrivalent HPV, n (%)^{a)}							
Single dose	13 (35.1%)	14 (40.0%)	4 (23.5%)	0	18 (3.7%)	2 (4.4%)	2 (25.0%)
Single dose – the need for additional doses depends on the epidemiological situation	4 (10.8%)	2 (5.7%)	0	0	4 (0.8%)	0	1 (12.5%)
Single annual dose	0	0	0	0	1 (0.2%)	0	0
Two doses	6 (16.2%)	10 (28.6%)	2 (11.8%)	0	94 (19.1%)	9 (20.0%)	2 (25.0%)
Three doses	8 (21.6%)	8 (22.9%)	9 (52.9%)	4 (80.0%)	330 (67.2%)	31 (68.9%)	2 (25.0%)
Booster dose every 10 years	1 (2.7%)	1 (2.9%)	0	0	1 (0.2%)	0	0
Sequential schedule with two vaccines (total of three doses)	2 (5.4%)	0	1 (5.9%)	0	27 (5.5%)	0	1 (12.5%)
No need for additional doses	0	0	0	0	1 (0.2%)	0	0
None of the above	3 (8.1%)	0	1 (5.9%)	1 (20.0%)	15 (3.1%)	3 (6.7%)	0
Total	37	35	17	5	491	45	8

^{a)} For physicians who prescribed the vaccine to adult patients.

^{b)} For physicians who prescribed the vaccine to older adult patients.

MMR, measles, mumps, and rubella; Tdap, adult tetanus-diphtheria-acellular; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; HPV, human papillomavirus.

Note: Proportions were determined based on the number of physicians of each medical specialty who stated to prescribe each vaccine to adult and/or older adult patients. Correct answers are highlighted.

Supplementary Table 12 – Knowledge of vaccines – Availability in Brazil's Unified Public Health System (SUS) – free of charge at the Basic Health Units by medical specialties

	Cardiology (n=244)	General Practice/Family Practice (n=85)	Endocrinology (n=80)	Geriatrics (n=26)	Gynecology (n=515)	Infectious Diseases (n=59)	Pulmonology (n=59)
MMR (measles, mumps and rubella), n (%)							
Yes, in adults and older adults	52 (58.4%)	29 (49.2%)	16 (53.3%)	6 (75.0%)	151 (48.6%)	19 (34.5%)	17 (63.0%)
Yes, only in adults	19 (21.3%)	23 (39.0%)	13 (43.3%)	2 (25.0%)	116 (37.3%)	33 (60.0%)	10 (37.0%)
Yes, only in older adults	2 (2.2%)	0	0	0	2 (0.6%)	0	0
Nor in adults or older adults	16 (18.0%)	7 (11.9%)	1 (3.3%)	0	42 (13.5%)	3 (5.5%)	0
Total	89	59	30	8	311	55	27
Hepatitis A, n (%)							
Yes, in adults and older adults	47 (56.6%)	26 (55.3%)	15 (48.4%)	4 (36.4%)	50 (33.1%)	18 (32.7%)	8 (44.4%)
Yes, only in adults	10 (12.0%)	7 (14.9%)	2 (6.5%)	4 (36.4%)	20 (13.2%)	10 (18.2%)	5 (27.8%)
Yes, only in older adults	1 (1.2%)	2 (4.3%)	0	0	1 (0.7%)	0	0
Nor in adults or older adults	25 (30.1%)	12 (25.5%)	14 (45.2%)	3 (27.3%)	80 (53.0%)	27 (49.1%)	5 (27.8%)
Total	83	47	31	11	151	55	18
Hepatitis B, n (%)							
Yes, in adults and older adults	145 (77.5%)	57 (76.0%)	47 (72.3%)	19 (82.6%)	338 (69.1%)	45 (76.3%)	28 (75.7%)
Yes, only in adults	23 (12.3%)	13 (17.3%)	9 (13.8%)	4 (17.4%)	115 (23.5%)	12 (20.3%)	6 (16.2%)
Yes, only in older adults	4 (2.1%)	1 (1.3%)	1 (1.5%)	0	4 (0.8%)	0	1 (2.7%)
Nor in adults or older adults	15 (8.0%)	4 (5.3%)	8 (12.3%)	0	32 (6.5%)	2 (3.4%)	2 (5.4%)
Total	187	75	65	23	489	59	37
Hepatitis A and B, n (%)							
Yes, in adults and older adults	53 (52.0%)	18 (33.3%)	11 (26.8%)	8 (66.7%)	83 (34.0%)	9 (22.0%)	11 (50.0%)
Yes, only in adults	9 (8.8%)	8 (14.8%)	4 (9.8%)	0	39 (16.0%)	3 (7.3%)	5 (22.7%)
Yes, only in older adults	5 (4.9%)	2 (3.7%)	1 (2.4%)	0	6 (2.5%)	0	1 (4.5%)
Nor in adults or older adults	35 (34.3%)	26 (48.1%)	25 (61.0%)	4 (33.3%)	116 (47.5%)	29 (70.7%)	5 (22.7%)
Total	102	54	41	12	244	41	22
Adult triple acellular bacterial vaccine (diphtheria, tetanus and acellular pertussis) - Tdap or Tdap-IPV, n (%)							
Yes, in adults and older adults	71 (66.4%)	31 (50.0%)	24 (57.1%)	11 (55.0%)	256 (58.2%)	19 (32.8%)	18 (56.3%)
Yes, only in adults	15 (14.0%)	12 (19.4%)	4 (9.5%)	4 (20.0%)	109 (24.8%)	12 (20.7%)	5 (15.6%)
Yes, only in older adults	3 (2.8%)	3 (4.8%)	4 (9.5%)	0	4 (0.9%)	0	3 (9.4%)
Nor in adults or older adults	18 (16.8%)	16 (25.8%)	10 (23.8%)	5 (25.0%)	71 (16.1%)	27 (46.6%)	6 (18.8%)
Total	107	62	42	20	440	58	32
Tetanus and diphtheria (diphtheria and tetanus) - dT, n (%)							
Yes, in adults and older adults	118 (83.1%)	55 (77.5%)	48 (92.3%)	20 (95.2%)	342 (79.5%)	54 (94.7%)	26 (78.8%)

	Cardiology (n=244)	General Practice/Family Practice (n=85)	Endocrinology (n=80)	Geriatrics (n=26)	Gynecology (n=515)	Infectious Diseases (n=59)	Pulmonology (n=59)
Yes, only in adults	13 (9.2%)	9 (12.7%)	2 (3.8%)	1 (4.8%)	69 (16.0%)	2 (3.5%)	5 (15.2%)
Yes, only in older adults	5 (3.5%)	1 (1.4%)	0	0	2 (0.5%)	0	1 (3.0%)
Nor in adults or older adults	6 (4.2%)	6 (8.5%)	2 (3.8%)	0	17 (4.0%)	1 (1.8%)	1 (3.0%)
Total	142	71	52	21	430	57	33
Varicella (Chickenpox), n (%)							
Yes, in adults and older adults	24 (47.1%)	14 (33.3%)	6 (40.0%)	2 (22.2%)	28 (26.7%)	12 (27.3%)	5 (38.5%)
Yes, only in adults	10 (19.6%)	4 (9.5%)	1 (6.7%)	1 (11.1%)	27 (25.7%)	8 (18.2%)	3 (23.1%)
Yes, only in older adults	1 (2.0%)	1 (2.4%)	1 (6.7%)	0	3 (2.9%)	1 (2.3%)	0
Nor in adults or older adults	16 (31.4%)	23 (54.8%)	7 (46.7%)	6 (66.7%)	47 (44.8%)	23 (52.3%)	5 (38.5%)
Total	51	42	15	9	105	44	13
Influenza (flu), n (%)							
Yes, in adults and older adults	151 (63.2%)	53 (64.6%)	47 (61.0%)	20 (76.9%)	365 (74.0%)	41 (69.5%)	30 (51.7%)
Yes, only in adults	4 (1.7%)	5 (6.1%)	1 (1.3%)	0	8 (1.6%)	1 (1.7%)	0
Yes, only in older adults	83 (34.7%)	22 (26.8%)	29 (37.7%)	6 (23.1%)	116 (23.5%)	16 (27.1%)	28 (48.3%)
Nor in adults or older adults	1 (0.4%)	2 (2.4%)	0	0	4 (0.8%)	1 (1.7%)	0
Total	239	82	77	26	493	59	58
Meningococcal Conjugate ACWY, n (%)							
Yes, in adults and older adults	24 (51.1%)	13 (31.7%)	3 (23.1%)	1 (25.0%)	24 (31.6%)	10 (22.2%)	7 (43.8%)
Yes, only in adults	4 (8.5%)	6 (14.6%)	0	1 (25.0%)	19 (25.0%)	3 (6.7%)	4 (25.0%)
Yes, only in older adults	3 (6.4%)	1 (2.4%)	0	0	1 (1.3%)	0	0
Nor in adults or older adults	16 (34.0%)	21 (51.2%)	10 (76.9%)	2 (50.0%)	32 (42.1%)	32 (71.1%)	5 (31.3%)
Total	47	41	13	4	76	45	16
Meningococcal B, n (%)							
Yes, in adults and older adults	27 (60.0%)	15 (38.5%)	2 (16.7%)	2 (50.0%)	22 (40.7%)	5 (14.3%)	5 (41.7%)
Yes, only in adults	6 (13.3%)	3 (7.7%)	0	1 (25.0%)	10 (18.5%)	3 (8.6%)	2 (16.7%)
Yes, only in older adults	2 (4.4%)	1 (2.6%)	0	0	2 (3.7%)	0	0
Nor in adults or older adults	10 (22.2%)	20 (51.3%)	10 (83.3%)	1 (25.0%)	20 (37.0%)	27 (77.1%)	5 (41.7%)
Total	45	39	12	4	54	35	12
Yellow Fever, n (%)							
Yes, in adults and older adults	175 (82.9%)	62 (79.5%)	53 (81.5%)	19 (79.2%)	301 (81.6%)	35 (59.3%)	36 (83.7%)
Yes, only in adults	32 (15.2%)	15 (19.2%)	12 (18.5%)	4 (16.7%)	65 (17.6%)	22 (37.3%)	6 (14.0%)
Yes, only in older adults	2 (0.9%)	0	0	0	1 (0.3%)	0	0
Nor in adults or older adults	2 (0.9%)	1 (1.3%)	0	1 (4.2%)	2 (0.5%)	2 (3.4%)	1 (2.3%)
Total	211	78	65	24	369	59	43
Anti-pneumococcal conjugated 13-valent vaccine, n (%)							
Yes, in adults and older adults	71 (34.1%)	27 (39.7%)	16 (36.4%)	9 (36.0%)	66 (50.4%)	10 (21.3%)	21 (36.8%)

	Cardiology (n=244)	General Practice/Family Practice (n=85)	Endocrinology (n=80)	Geriatrics (n=26)	Gynecology (n=515)	Infectious Diseases (n=59)	Pulmonology (n=59)
Yes, only in adults	5 (2.4%)	1 (1.5%)	0	0	4 (3.1%)	1 (2.1%)	2 (3.5%)
Yes, only in older adults	47 (22.6%)	14 (20.6%)	10 (22.7%)	3 (12.0%)	25 (19.1%)	3 (6.4%)	4 (7.0%)
Nor in adults or older adults	85 (40.9%)	26 (38.2%)	18 (40.9%)	13 (52.0%)	36 (27.5%)	33 (70.2%)	30 (52.6%)
Total	208	68	44	25	131	47	57
Anti-pneumococcal conjugated 23-valent vaccine, n (%)							
Yes, in adults and older adults	66 (33.8%)	21 (31.8%)	8 (21.6%)	10 (38.5%)	66 (52.0%)	23 (39.7%)	30 (51.7%)
Yes, only in adults	4 (2.1%)	3 (4.5%)	0	0	4 (3.1%)	2 (3.4%)	2 (3.4%)
Yes, only in older adults	42 (21.5%)	19 (28.8%)	7 (18.9%)	9 (34.6%)	23 (18.1%)	17 (29.3%)	17 (29.3%)
Nor in adults or older adults	83 (42.6%)	23 (34.8%)	22 (59.5%)	7 (26.9%)	34 (26.8%)	16 (27.6%)	9 (15.5%)
Total	195	66	37	26	127	58	58
Zoster, n (%)							
Yes, in adults and older adults	32 (36.0%)	13 (25.5%)	6 (19.4%)	3 (13.0%)	84 (27.3%)	7 (17.1%)	8 (42.1%)
Yes, only in adults	2 (2.2%)	5 (9.8%)	0	0	14 (4.5%)	0	1 (5.3%)
Yes, only in older adults	8 (9.0%)	6 (11.8%)	2 (6.5%)	2 (8.7%)	60 (19.5%)	3 (7.3%)	0
Nor in adults or older adults	47 (52.8%)	27 (52.9%)	23 (74.2%)	18 (78.3%)	150 (48.7%)	31 (75.6%)	10 (52.6%)
Total	89	51	31	23	308	41	19
Dengue, n (%)							
Yes, in adults and older adults	40 (72.7%)	19 (63.3%)	7 (58.3%)	2 (66.7%)	44 (47.3%)	3 (25.0%)	6 (75.0%)
Yes, only in adults	5 (9.1%)	1 (3.3%)	1 (8.3%)	1 (33.3%)	12 (12.9%)	1 (8.3%)	0
Yes, only in older adults	0	0	0	0	0	0	0
Nor in adults or older adults	10 (18.2%)	10 (33.3%)	4 (33.3%)	0	37 (39.8%)	8 (66.7%)	2 (25.0%)
Total	55	30	12	3	93	12	8
Bivalent Fever, n (%)							
Yes, in adults and older adults	14 (36.8%)	9 (20.5%)	2 (9.5%)	0	57 (16.4%)	1 (2.9%)	2 (18.2%)
Yes, only in adults	8 (21.1%)	14 (31.8%)	2 (9.5%)	2 (66.7%)	95 (27.3%)	7 (20.6%)	3 (27.3%)
Yes, only in older adults	0	0	1 (4.8%)	0	1 (0.3%)	1 (2.9%)	0
Nor in adults or older adults	16 (42.1%)	21 (47.7%)	16 (76.2%)	1 (33.3%)	195 (56.0%)	25 (73.5%)	6 (54.5%)
Total	38	44	21	3	348	34	11
Quadrivalent HPV, n (%)							
Yes, in adults and older adults	10 (27.0%)	9 (25.7%)	2 (11.8%)	1 (20.0%)	67 (13.6%)	3 (6.7%)	2 (25.0%)
Yes, only in adults	9 (24.3%)	10 (28.6%)	3 (17.6%)	1 (20.0%)	135 (27.5%)	15 (33.3%)	4 (50.0%)
Yes, only in older adults	1 (2.7%)	0	0	0	4 (0.8%)	0	0
Nor in adults or older adults	17 (45.9%)	16 (45.7%)	12 (70.6%)	3 (60.0%)	285 (58.0%)	27 (60.0%)	2 (25.0%)
Total	37	35	17	5	491	45	8

	Cardiology (n=244)	General Practice/Family Practice (n=85)	Endocrinology (n=80)	Geriatrics (n=26)	Gynecology (n=515)	Infectious Diseases (n=59)	Pulmonology (n=59)
--	-----------------------	-----------------------------------------------	-------------------------	----------------------	-----------------------	----------------------------------	-----------------------

Note: Proportions were determined based on the number of physicians of each medical specialty who stated to prescribe each vaccine to adult and/or older adult patients. Correct answers are highlighted.

Supplementary Table 13 – Comparison of the populations of physicians in Brazil, invited to participate in the study, and completing the survey

	Brazil**	Invited Physicians***	Survey
Number of physicians, n	452 801	76 104	1068
Sex (female), n (%)	45.6%	36.7%	53.7%
Age (mean)	45.4 years	Not available	44.70 years
Region, %			
North	4.6%	2.2%	4.5%
Northeast	17.8%	11.3%	17.9%
Midwest	8.3%	5.0%	8.2%
Southeast	54.1%	70.8%	54.3%
South	15.1%	10.6%	15.1%
Primary area of practice, n (%)			
Public	21.6%	Not available	4.8%
Private	26.9%	Not available	33.6%
Public-private	51.5%	Not available	61.6%
Medical specialty*, n (%)			
Cardiology	13420 (22.9%)	14662 (19.3%)	244 (22.8%)
GP/FP	4682 (8.0%)	35697 (46.9%)	85 (8.0%)
Geriatrics	1405 (2.4%)	1737 (2.3%)	26 (2.4%)
Gynecology	28280 (48.2%)	13259 (17.4%)	515 (48.2%)
Endocrinology	4396 (7.5%)	4166 (5.5%)	80 (7.5%)
Pulmonology	3253 (5.5%)	3749 (4.9%)	59 (5.5%)
Infectious Diseases	3229 (5.5%)	2834 (3.7%)	59 (5.5%)

*Percentages (%) correspond to the number of physicians in each medical specialty divided by the sum of physicians in each medical specialty of interest.

**According to Mário Scheffer et al. Demografia Médica no Brasil 2015. [Internet] 2015 [Accessed on 06 Set 2017]. Available at:
<https://www.usp.br/agen/wpcontent/uploads/DemografiaMedica30nov2015.pdf>.

***Includes all invited physicians – those already registered in the Fine Panel at the time of recruitment and those who registered in the panel only after being invited to complete the survey.

Sample size stratification

The number of physicians required to complete the survey per region was estimated based on the number of active physicians in Brazil (total and per region) (4), as presented below.

Region	Active Physicians	% for stratification*	Total number of required answers**
North	21584	4	48
Northeast	85954	18	191
Midwest	39508	8	88
Southeast	261852	54	581
South	72482	15	161
Total	481380	100	1068

*Rational: Number of active physicians in the region/ total of active physicians in Brazil (4)

**Rational: % for stratification X number of required answers to the survey (1068)

On the other hand, the number of physicians required to complete the survey per medical specialty was estimated, based on the number of physicians of each medical specialty to be included in the study in Brazil (5). This process was followed for each medical specialty except General Practice. This is because the number of physicians belonging exclusively to General Practice is reduced in Brazil, and it was expected to be considerably lower than the number presented in the reference used (in which physicians with more than one medical specialty were considered) (5).

As such, to estimate the number of physicians working exclusively as general practitioners, a different procedure was followed. Initially, based on the Regional Council of Medicine of São Paulo's website (6), the number of active physicians working exclusively as general practitioners was determined, and the proportion of these physicians in São Paulo was calculated. Subsequently, the number of general practitioners in the remaining Southeast region's states was determined, assuming the same proportion found in São Paulo. Finally, the proportion of general practitioners in the Southeast region was estimated and used to assess the number of physicians belonging exclusively to this specialty in the remaining Brazilian regions, which allowed to obtain the total number in the country.

Specialty	Physicians per medical specialty	% for stratification*	Total number of required answers**
Cardiology	13420	23	244
GP/FP	4682	8	85
Endocrinology	4396	7	80
Geriatrics	1405	2	26
Gynecology	28280	48	515
ID	3229	6	59
Pulmonology	3253	6	59
Total	87205	100	1068

GP/FP, general practitioners/family physicians.

*Rational: Number of physicians from each specialty/ total number of physicians from the medical specialties to be included in the study.

**Rational: % for stratification X number of required answers to the survey (1068)

Finally, based on this information, the number of survey answers from physicians of each medical specialty per Brazilian region was determined.

References

1. Sociedade Brasileira de Imunizações (SBIm). Calendários de Vacinação - Pacientes Especiais 2015-2016.
2. Ministério da Saúde. Nota Informativa Nº 135-SEI/2017-CGPNI/DEVIT/SVS/MS. [Internet] 2017 Accessed on 13 Nov 2018]. Available at: <http://www.smp.org.br/arquivos/site/protocolo-meningite-5-edicao-completo-3-2.pdf>.
3. Ministério da Saúde. Calendário Nacional de Vacinação 2018 . [Internet] 2018 [Accessed on 12 Jul 2019]. Available at: <http://portalarquivos.saude.gov.br/campanhas/pni/>.
4. Conselho Federal de Medicina. Médicos ativos por região. [Internet] 2017 [Accessed on 16 Aug 2017]. Available at: http://portal.cfm.org.br/index.php?option=com_estatistica.
5. Mário Scheffer et al. Demografia Médica no Brasil 2015. [Internet] 2015 [Accessed on 06 Set 2017]. Available at: <https://www.usp.br/agen/wpcontent/uploads/DemografiaMedica30nov2015.pdf>.
6. Conselho Regional de Medicina do Estado de São Paulo. Pesquisa detalhada de médicos no CREMESP. [Internet] 2017 [Accessed on 25 Jan 2018]. Available at: <https://www.cremesp.org.br/?siteAcao=GuiaMedico&pesquisa=avancada>.